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1. Summary 
The two members of the epidermal growth factor receptor (EGFR) family, 
ErbB2/HER2 and ErbB3/HER3, act as key oncogenes in cancer cells. 
ErbB3/HER3 is a receptor tyrosine kinase (RTK) believed to have an 
impaired kinase activity due to two uncharacteristic amino acid residues in 
the tyrosine kinase consensus sequences. Heregulin (HRG), a specific 
ligand for ErbB3/HER3 promotes the heterodimerization with the RTK 
ErbB2/HER2 and transphosphorylation of its intracellular domain. 
ErbB3/HER3 preferentially forms heterodimers with ErbB2/HER2, which 
induce the most potent mitogenic signal among EGFR family members. 
We investigated the HRG-dependent mechanism by which the 
cytoplasmic proline-rich tyrosine kinase PYK2 becomes tyrosine 
phosphorylated, its role in the MAPK pathway and subsequent effects on 
the invasive properties of tumour cells. The results presented in this thesis 
show that ErbB3/HER3 is able to phosphorylate PYK2 upon stimulation 
with HRG. In glioma-derived cell lines PYK2 is constitutively associated 
with ErbB3/HER3 but not ErbB2/HER2 and stimulation with HRG results in 
PYK2 tyrosine phosphorylation requiring active kinase functions of both 
ErbB2/HER2 and ErbB3/HER3. Our data suggest a pivotal role for PYK2 
as a regulator of the invasive capacity of glioma cells and, furthermore, 
show that ErbB3/HER3 is a functional RTK with narrow substrate 
specificity. 
Moreover, this study also aimed at determining whether ErbB3/HER3 
plays, beside ErbB2/HER2, a physiologically relevant role in transmitting 
proliferative and migratory signals in breast cancer cell lines. An agonistic 
monoclonal antibody against ErbB2/HER2, Herceptin®, has previously 
been shown to interfere with ErbB2/HER2 signalling and is therapeutically 
effective in humans. Therefore, we dissected the effects of an antibody 
against ErbB3/HER3 (α-HER3ECD) and Herceptin® on HRG-mediated 
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signalling and analyzed the inhibitory potential of α-HER3ECD on breast 
cancer cell growth and motility.  
These data indicate that this antibody is a more potent inhibitor than 
Herceptin® for the HRG-mediated signal transduction processes. 
Furthermore, our results reinforce the notion that ErbB3/HER3 could be a 
key target in cancer drug designing and show the great potential of anti-
ErbB3/HER3 antibodies for the therapy of breast cancer and other 
malignancies characterized by the overexpression of ErbB3/HER3. 
  
 
Introduction  5 
2. Introduction 
2.1. The epidermal growth factor receptor family 
2.1.1. ErbB1/EGFR-the “godfather” of the EGFR family 
ErbBs are typical receptor tyrosine kinases that were implicated in cancer 
in the early 1980s when the avian erythroblastosis tumour virus was found 
to encode an aberrant form of the human epidermal growth factor  
receptor (also known as Erb1, HER1 or EGFR) (Downward et al., 1984b). 
The four ErbBs share an overall structure of two cysteine-rich stretches in 
their extracellular region, and a kinase domain flanked by a carboxy-
terminal tail with tyrosine autophosphorylation sites (Downward et al., 
1984a; Riedel et al., 1987) (Fig. 1). 
 
 
Fig.1: Schematic representation of EGFR family RTKs 
 
With few exceptions (for example, haematopoietic cells), ErbB proteins are 
expressed in cells of mesodermal and ectodermal origins (Yarden and 
Sliwkowski, 2001). The EGFR was the first signal-generating protein and 
protooncogene with known normal function to be cloned molecularly 
(Ullrich et al., 1984). Several lines of evidence indicate a prominent role of 
the EGFR in cancer: its functional role as a protooncogene in viruses, the 
pathophysiological effect of EGFR mutants and its overexpression in 
several cancer types are well documented (Gill, 1989). Furthermore, its 
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overexpression correlates inversely with estrogen receptor (ER) status, is 
often detected in invasive ductal carcinomas and is associated with poor 
prognosis. 
 
2.1.2. ErbB2/HER2-an essential breast cancer oncogene 
A member of the EGFR family, ErbB2/HER2 (known as neu) has been 
identified as one of the key oncogenes in invasive breast cancer (Natali et 
al., 1990; Schechter et al., 1985; Slamon et al., 1989). ErbB2/HER2 gene 
amplification is found in 20-30% of all diagnosed breast cancer patients 
and a significant correlation between ErbB2/HER2 overexpression and 
reduced survival of breast cancer patients has been found (Slamon et al., 
1989). Therefore, ErbB2/HER2 became a target in breast cancer therapy 
due to its signalling properties in breast cancer. It is important in breast 
cancer therapy also from the prognostic point of view. Moreover, ErbB2 is 
not only a prognostic factor but also a predictive marker for responses to 
various therapeutic agents used in breast cancer therapy (Ross and 
Fletcher, 1998) (Tsongalis and Ried, 2001). ErbB2/HER2 overexpression 
correlates with a lack of response to endocrine therapy and 
chemotherapeutic agents.  
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2.1.3. ErbB3/HER3-the “neglected” receptor of the EGFR family 
 
Another member of the EGFR family, HER3 (ErbB3), is consistently 
overexpressed together with ErbB2/HER2 in invasive breast cancer and a 
correlation between the expression of ErbB2/HER2-ErbB3/HER3 and the 
progression from a non-invasive to an invasive stage has been shown 
(Alimandi et al., 1995; deFazio et al., 2000; Naidu et al., 1998). 
ErbB3/HER3 is a receptor tyrosine kinase, which was reported to have a 
weak activity (Guy et al., 1994); it forms with ErbB2/HER2 a high-affinity 
complex for its natural ligand HRG (Sliwkowski et al., 1994). ErbB3 is 
expressed in several cancers, but there is no evidence for gene 
amplification and overexpression is limited. However, a recent 
multinational study found that co-expression of ErbB2/HER2 with EGFR or 
ErbB3/HER3 in oral squamous-cell carcinoma was significant and it 
critically improved the predicting power (Xia et al., 1999). Therefore, the 
role of ErbB3/HER3 as a prognostic marker could become more important 
at least in oral squamous-cell carcinoma. Similarly, analysis of prostate 
cancer suggests the existence of a paracrine loop involving Neuregulin 1 
(NRG1) and the ErbB2/HER2–ErbB3/HER3 heterodimer (Lyne et al., 
1997). 
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2.2. The NRGs-Ligands of the ErbB family 
All high-affinity ErbB ligands have an EGF-like domains and three 
disulphide-bonded intramolecular loops (Jones et al., 1999) (Fig.2). 
 
 
Fig.2: Schematic representation of the human HRG family. 
 
This receptor-binding domain is usually part of a large transmembrane 
precursor containing other structural motifs such as immunoglobulin-like 
domain, heparin-binding sites and glycosylated linkers. Expression and 
processing of the precursor are highly regulated.  
Neuregulins (NRGs) play a regulatory role in many cell systems 
(Buonanno and Fischbach, 2001). The effects exerted by NRGs on the 
glial cells during development has been extensively characterized (Garratt 
et al., 2000). NRGs are involved in the activation of astrocyte migration 
and have a particularly potent effect on their proliferation and 
differentiation by activating the MAPK pathway through SHC and PI3-K 
(Faber-Elman et al., 1996; Wallasch et al., 1995). Four neuregulins, NRG1 
- NRG4, are a subfamily of structurally related glycoproteins that are 
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produced by proteolytic processing of transmembrane precursors (Busfield 
et al., 1997; Carraway et al., 1997; Chang et al., 1997; Fischbach and 
Rosen, 1997; Harari et al., 1999; Ishiguro et al., 1998; Zhang et al., 1997). 
The multitude of NRG1 isoforms, which include neu differentiation factor 
(NDF), neuronal acetylcholine receptor-inducing activity protein (ARIA), 
glial growth factor (GGF), sensorimotor-derived factor (SMDF) and the 
HRGs, reflects their multiple growth- and differentiation-regulating 
activities in a variety of different biological systems (Holmes et al., 1992). 
Expression of HRGs was detected in the central and peripheral nervous 
systems, where they exert biological activities at neuromusclar junctions, 
and junctions between neurons and Schwann cells, respectively (Orr-
Urtreger et al., 1993). Other mebmers of the HRG family are important in 
the pathology of a wide variety of cell types and play a role in cancer 
progression (Lyne et al., 1997). It could be demonstrated that the most 
invasive breast cancer cell lines, lacking ER and consequently 
responsiveness to hormone therapy, overexpress HRG in an autocrine 
manner (deFazio et al., 2000). 
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2.3. The EGFR signalling network 
2.3.1. General Overview 
The components of the EGFR signalling pathway are evolutionarily 
ancient and, at first glance, resemble a simple growth factor signalling 
system: ligand binding to a monomeric receptor tyrosine kinase activates 
the cytoplasmic catalytic function by promoting receptor dimerization and 
self-phosphorylation on tyrosine residues (Yarden and Sliwkowski, 2001). 
The latter serve as docking sites for various adaptor proteins or enzymes, 
which simultaneously initiate many signalling cascades to produce a 
physiological outcome (Fig. 3). In higher eukaryotes, however, the simple 
linear pathway has evolved into a richly interactive, multilayered network, 
in which combinatorial expression and activation of components permits 
context-specific biological responses throughout development and 
adulthood. 
 
 
 
Fig. 3: Signalling by ErbB homodimers in comparison with ErbB2/HER2-containing 
heterodimers. Receptors are shown as two lobes connected by a transmembrane 
stretch. Binding of a ligand (EGF-like or NRG) to the extracellular lobe of ErbB1/EGFR, 
ErbB3/HER3 (note inactive kinase, marked by a cross) or ErbB4/HER4 induces 
homodimer formation. When ErbB2/HER2 is overexpressed, heterodimers form 
preferentially. Unlike homodimers, which are either inactive (ErbB3/HER3 homodimers) 
or signal only weakly, ErbB2/HER2-containing heterodimers have attributes that prolong 
and enhance downstream signalling (green box) and their outputs (yellow box). 
Apparently, homodimers of ErbB2/HER2 are weaker signalling complexes than 
heterodimers containing ErbB2/HER2. (taken from (Yarden and Sliwkowski, 2001)). 
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Examination of the intracellular and extracellular domains of the ErbBs 
provides a satisfactory explanation as to why a horizontal network of 
interactions is crucial to the ErbB signalling pathway: ErbB3/HER3 
represents a RTK whose kinase activity is significantly weaker than that of 
the EGFR in a transphosphorylation reaction, which appears to be due to 
differences in two kinase domain amino acid residues that are conserved 
in other RTK family members (Kraus et al., 1989), whereas ErbB2/HER2 
seems to have no direct ligand (Klapper et al., 1999). Therefore, in 
isolation neither ErbB2/HER2 nor ErbB3/HER3 can support linear 
signalling (Fig.3). Most inter-receptor interactions are mediated by ligands, 
and ErbB2/HER2-containing heterodimers are formed preferentially 
(Graus-Porta et al., 1997; Tzahar et al., 1996). Nevertheless, 
overexpression of a specific receptor can bias dimer formation, especially 
in the case of ErbB2/HER2, whose homodimers can spontaneously form 
in ErbB2/HER2-overexpressing cells. Many cancers of epithelial origin 
have an amplification of the ErbB2/HER2 gene, which pushes the 
equilibrium towards ErbB2/HER2 homodimer and heterodimer formation 
(Fig.3).
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2.3.2. The Erb2/HER2-Erb3/HER3 signalling 
The transmission of a mitogenic signal involves binding of HRG either to 
ErbB3/HER3 or to ErbB4/HER4, which then heterodimerize with 
ErbB2/HER2 and are thought to become transphosphorylated at their C-
terminus by the ErbB2/HER2 kinase (Wallasch et al., 1995; Yarden and 
Sliwkowski, 2001). Upon HRG stimulation, ErbB2/HER2-ErbB3/HER3 
heterodimers deliver the most potent and long lasting proliferative signal 
among the possible combinatorial pairs of HER members (Fig.4). This 
characteristic is due to the ability of ErbB2/HER2-ErbB3/HER3, but not 
other combinations, to continue signalling within the endosome after 
ligand-induced internalization (Lenferink et al., 1998; Yarden and 
Sliwkowski, 2001). Taken together, these data point out that not 
ErbB2/HER2 alone but the formation of ErbB2/HER2-ErbB3/HER3 
complexes plays a crucial role in mitogenic signalling.  
ErbB4, whose expression pattern is relatively limited, has several isoforms 
that differ in their juxtamembrane and carboxy-termini, resulting in 
differences in the recruitment of PI3-K (Elenius et al., 1999), which 
activates cell-survival pathways. However, the role of ErbB4/HER4 and its 
signalling pathways in cancer are not clear. 
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Fig. 4: The ErbB signalling network. (a) Ligands and the ten dimeric receptor 
combinations comprise the input layer. Numbers in each ligand block indicate the 
respective high-affinity ErbB receptors (Jones et al., 1999). For simplicity, specificities of 
receptor binding are shown only for EGF and NRG4. ErbB2/HER2 binds no ligand with 
high affinity, and ErbB3/HER3 homodimers are catalytically inactive (crossed kinase 
domains). Trans-regulation by G-protein-coupled receptors (such as those for 
lysophosphatidic acid (LPA), thrombin and endothelin (ET)), and cytokine receptors is 
shown by wide arrows. (b) Signalling to the adaptor/enzyme layer is shown only for two 
receptor dimers: the weakly mitogenic ErbB1/EGFR homodimer, and the relatively potent 
ErbB2–ErbB3 heterodimer. Only some of the pathways and transcription factors are 
represented in this layer. (c) How they are translated to specific types of output is poorly 
understood at present (taken from (Yarden and Sliwkowski, 2001)). 
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The Ras- and SHC-activated MAPK pathway is an invariable target of all 
ErbB ligands, and the PI3-K-activated AKT pathway and p70S6K/p85S6K 
pathway are downstream of most active ErbB dimers. Signalling 
molecules, such as PI3-K, SHC and GRB7, subsequently bind to the 
phosphorylated C-terminus of ErbB3/HER3 and thereby activate 
downstream pathways resulting in a mitogenic response (Fiddes et al., 
1998). The potency and kinetics of PI3-K activation differ, however, 
probably because PI3-K couples directly with ErbB3/HER3 and 
ErbB4/HER4, but indirectly with ErbB1/EGFR and ErbB2/HER2 (Soltoff 
and Cantley, 1996). These findings indicate that ErbB3/HER3 is indeed a 
crucial coordinator of the ErbB signalling network. 
However, while ErbB2/HER2 was the objective of intensive anti-cancer 
drug-designing studies, ErbB3/HER3, due to its reportedly impaired 
tyrosine kinase activity, was not considered by pharmacological research 
as a target so far. 
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2.4. PYK2-a member of the focal adhesion kinase 
(FAK) family 
A recently identified member of the focal adhesion kinase family PYK2, 
also designated as FAK2, CAK-β, RAFTK or CADTK, was shown to be a 
link in G protein-coupled receptor-induced MAPK activation (Dikic et al., 
1996; Girault et al., 1999; Lev et al., 1995). Phosphorylation of PYK2 leads 
to recruitment of Src-family kinases and to activation of extracellular 
signal-regulated kinases (ERKs). PYK2 is predominantly expressed in the 
central nervous system and in cells and tissues derived from the 
hematopoietic lineage, where it is found throughout the cytoplasm but 
concentrated in the perinuclear region (Andreev et al., 1999). PYK2 can 
be activated by stimuli that increase intracellular calcium levels (Avraham 
et al., 2000), and by stress factors such as hyperosmotic shock, UV light 
or tumour necrosis factor α, thereby inducing JNK (Tokiwa et al., 1996; Yu 
et al., 1996). However, the molecular details of the PYK2 activation 
mechanism are unknown. 
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2.5. Overview of cancer progression 
It is generally accepted that malignant transformation involves genetic and 
epigenetic changes that derail common regulatory mechanisms and result 
in uncontrolled cellular proliferation and/or aberrant programmed cell death 
or apoptosis (Holliday, 1996; Simons, 1995). These cellular abnormalities, 
hallmarks of a carcinogenic process, are frequently associated with 
molecular alterations involving activation of proto-oncogenes and 
inactivation of tumour suppressor genes as a result of genetic 
predisposition and/or exposure to physical (e.g., radiation), chemical (e.g., 
carcinogens, dietary components) and biological (e.g., viruses) 
environmental factors (Couch, 1996). A central challenge for cancer 
biology is to understand the cellular and molecular processes that drive 
normal cells to neoplastic growth.  
 
2.5.1. Gliomagenesis 
Gliomas are a large collection of primary brain tumours that have 
morphology and gene-expression characteristics similar to glia, astrocytes 
and oligodendrocytes, which together support the functions of neurons in 
the brain (Berens and Giese, 1999). Because these tumours arise in the 
central nervous system and affect surrounding brain structures, patients 
with gliomas commonly develop symptoms that include headaches and 
seizures, or focal neurological alterations that cause weakness of one limb 
or language disturbance. Most gliomas arise sporadically and are not 
inherited within families; patients with gliomas however, frequently have a 
history of diverse cancer types. About 30,000 patients in the United States 
are newly diagnosed with a glioma each year (Greenlee et al., 2000). 
Glioblastoma multiforme (GBM), the most malignant tumour of the primary 
central nervous system, arises from neoplastic transformation of glioblasts, 
which include type 1 and type 2 astrocytes. Additionally, GBMs are 
heterogenous intraparenchymal masses that show evidence of necrosis 
and hemorrhage (Holland, 2001). The central nervous system stem cell 
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gives rise to neuronal and glial progenitors, which subsequently give rise 
to the mature cell types found in the brain. Specific signal-transduction 
pathways have been shown to control the differentiation of precursor cells 
into mature glia. In cell culture, platelet-derived growth factor (PDGF) 
causes the oligodendrial progenitor population to proliferate (McKinnon et 
al., 1990), and cooperates with fibroblast growth factor 2 (FGF2) to 
prevent that population`s further differentiation into mature 
oligodendrocytes (Bogler et al., 1990; Mayer et al., 1993). Epidermal 
growth factor (EGF) and cilliary neurotrophic factor (CNTF) force glial 
progenitors towards astrocytic and oligodendrocytic differentiation (Fig.5) 
(Mayer et al., 1993; Rajan and McKay, 1998).  
 
 
 
Fig.5: Cellular differentiation in the central nervous system. Stages of CNS cell 
differentiation; from stem cell to differentiated astrocyte, oligodendrocyte and neuron. 
Growth factors that promote the progression of one cell type to another are indicated in 
green, those that inhibit progression of one cell type to another are in red, and those that 
induce proliferation and maintain cells at a given stage of development are indicated in 
blue (taken from (Holland, 2001)). 
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During development, glioblasts migrate out of the subventricular zone of 
the brain into the developing white matter, while differentiating and 
proliferating en route (Altman, 1966; Goldman, 1992). This inherent ability 
of astrocytes to migrate represents a key feature of gliomas, during 
invasion of tumour cells into surrounding tissue. Although the effects of 
these growth factors on glial development are well documented, the 
understanding of how these pathways control cell fate and proliferation in 
glial development is still incomplete. 
 
2.5.2. Breast cancer 
Breast cancer is the most common malignancy among women in the US 
and accounts for one million new cases every year. It constitutes 30% of 
all new female cancers cases diagnosed, and accounts for 18% of female 
cancer deaths in the U.S. (Greenlee et al., 2000). Progress has been 
made in defining some of the critical processes associated with the 
development of breast cancer. However, the specific biochemical and 
molecular mechanisms underlying many of these complex carcinogenic 
events still remain to be elucidated.  
The vast majority of breast cancers are carcinomas, the malignant 
tumours of the epithelia. Based upon histological evaluations, 
development of breast cancer has been postulated to be a multi-step 
process and follows a defined sequence of qualitatively different events 
(Russo et al., 1993; Russo et al., 1998) (Fig. 6), as documented for a 
number of other malignancies (Farber, 1984; Klein and Klein, 1985). In 
human breast, ductal hyperplasia and atypical ductal hyperplasia 
represent the initial stages of neoplastic growth and progress gradually to 
ductal carcinoma in situ, invasive ductal carcinoma and ultimately 
metastasis, even though normal cells could directly give rise to ductal 
carcinoma in situ or invasive ductal carcinoma (Page and Dupont, 1990; 
Russo et al., 1993) (Fig. 6).  
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Fig. 6: In vivo model of neoplastic progression of human breast carcinomas. 
 
Growth factors that bind to and activate receptor tyrosine kinases 
expressed in epithelial cells have distinct roles in mammary gland 
development. Interestingly, overexpression of many of these ligands has 
also been associated with mammary tumourigenesis. Several groups have 
established transgenic mice bearing TGF-α, an EGFR-specific ligand, 
under the control of either the MMTV-LTR (mouse mammary tumour virus-
long terminal repeat) or metallothionein promoter (Jhappan et al., 1990; 
Matsui et al., 1990; Sandgren et al., 1990). 
In two studies, TGF-α expression resulted in epithelial hyperplasia and 
dysplasia, with only a small number of multiparous animals developing 
mammary tumours (Matsui et al., 1990; Sandgren et al., 1990). 
The remaining study reported reduced penetration of the mammary ducts 
into the fat pad and an increase in the number of actively dividing epithelial 
cells, which were not restricted to the terminal end buds (Jhappan et al., 
1990). More recently, a member from the NDF (Neu differetiation factor) 
family of ligands, which bind directly to ErbB3/HER3 and ErbB4/HER4, 
has also been found to be expressed in the mammary glands of 
transgenic mice (Krane and Leder, 1996). 
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Fig. 7: Hypothetical model for the role of ErbB3/HER3 in Neu-induced mammary 
tumourigenesis. ErbB2/HER2 homodimers are formed as a consequence of somatic 
mutations or ligand-induced activation, leading to activation of Ras-GTP and induction of 
cell proliferation. Activation of Neu results in the transphosphorylation of ErbB3/HER3, 
which, in turn, recruits the PI3-K pathway. Activation of PI3-K stimulates AKT/PKB, which 
then provides a cell survival signal. A potential mechanism by which translation of 
ErbB3/HER3 may be upregulated via inhibition of 4E-BP1 is also shown (taken from 
(Siegel et al., 2000)). 
 
Multiparous animals expressing NDF-β2 develop palpable mammary 
tumours at an average age of 357 days. These data demonstrate that 
ligands that bind and activate different members of the EGFR family exert 
similar proliferative effects on mammary epithelial cells (Fig. 7). This may 
reflect the ability of TGF-α and NDF-β2 to induce heterodimers between 
various EGFR family members, with Neu representing a common 
component of the activated receptor complex. Finally, it is evident that 
both ligands are necessary, but not sufficient, for mammary 
tumourigenesis given the long latency and focal nature of the tumours that 
arise in these mice.
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2.6. Therapeutic antibodies in cancer treatment 
2.6.1. General overview 
Antibodies have for many decades been anticipated as the ideal molecule 
for the therapy of cancer and infectious diseases (Borrebaeck, 1989). This 
particular therapeutic modality has grown to the point where it constitutes 
approximately 30% of all clinical trials (excluding vaccine and gene 
therapy) registered by the Food and Drug Administration (FDA) in the USA 
(Borrebaeck, 1999) (Tab. 1). 
 
Product name Specificity Indication Year of 
approval 
Orthoclone OKT®3 
(muromonab-CD3) 
CD3 Acute kidney transplant 
rejection 
1986 
ReoPro® (abciximab) gpIIb/IIIa Prevention of bloodclotting 
Refractory unstable angina 
1994 
Rituxan® (rituximab) CD20 Non-Hodgkin`s lymphoma 1997 
Zenapax® (daclizumab) CD25 
(IL2R) 
Acute kidney transplant 
rejection 
1997 
Remicade® (infliximab) TNF-α Crohn`s disease 
Rheumatoid arthritis 
1999 
Simulect® (basiliximab) CD25 
(IL2R) 
Acute kidney transplant 
rejection 
1998 
Synagis® (palivizumab) RSV Respiratory syncytia virus 1998 
Thymoglobulin® Polyclonal 
Abs 
Acute kidney transplant 
rejection 
1998 
Herceptin® 
(trastuzumab) 
HER2 Metastatic breast cancer 1998 
Nabi-HB™ Polyclonal 
Abs 
Hepatitis B 1999 
CroFab® Snake 
venom 
Rattlesnake antidote 2000 
Campath® 
(alemtuzumab) 
CD52 Chronic lymphocytic leukaemia 2001 
Mylotarg™ 
(gemtuzumab, 
ozogamicin) 
CD33 Acute myeloid leukaemia 2000 
Tab. 1: FDA-approved therapeutic antibodies.1 
                                                     
1 New Medicines in Development: Biotechnology: a 2000 survey at 
URL:http://www.pharma.org/searchcures/newsmeds/biotech2000/bio00.pdf 
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Despite the fact that work on antibodies targeting intracellular molecules is 
being performed, most targets for therapeutic antibodies are extracellular 
molecules (Marasco and Dana Jones, 1998). Depending on the indication, 
the type of targets may differ significantly as may the need for partial or 
total antibody-mediated effect. Targeting tumour cells, a total (or close to 
total) elimination of all malignant cells is fundamental, putting tremendous 
demands on the distribution of the target molecule, the ability of the 
therapeutic antibody to reach and bind to all tumour cells and the effector 
system mediating the toxic effect to the tumour cell. In contrast, antibodies 
that exert their function through blocking signalling between or interfering 
with, for example, TNF¯TNFR (tumour necrosis factor receptor) or IL-2¯IL-
2R (interleukin-2 receptor) interactions may be effective even if the 
blocking is not 100% efficient (Feldmann and Maini, 2001) (Berard et al., 
1999). 
Many therapeutic antibodies have been designed to exert their effect when 
coupled to immunotoxins, drugs or radioisotopes (Goldenberg, 1999; 
Riethmuller et al., 1998). The effector mechanisms associated with naked 
antibodies have been considered to be associated with the ability of the 
antibody to recruit natural effector mechanisms like ADCC (antibody-
dependent cellular cytotoxicity) and CDC (complement-dependent 
cytotoxicity). Target molecules that are normally involved in cell signalling-
for example, those that control cell growth or are involved in mechanisms 
participating in apoptosis-might be ideal targets for naked therapeutic 
antibodies. Interestingly, cells normally considered to mediate ADCC might 
also aid cytotoxic activity through the cross-linking of the therapeutic 
antibody on the surface of the target cell via their Fcγ-receptors, in addition 
to the ADCC effect (Cragg et al., 1999; Shan et al., 2000). This suggests 
that novel targets for cancer therapy should be sought among functionally 
associated surface molecules. 
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2.6.2. Herceptin®-the “gold standard” in antibody therapy 
The development of a monoclonal antibody against ErbB2/HER2, 4D5, 
and its subsequent humanized counterpart Herceptin® (Trastuzumab), 
which has recently been approved by the FDA, represents the hitherto 
state-of-the-art agent against ErbB2/HER2-overexpressing metastatic 
breast carcinoma (Fendly et al., 1987; Hudziak et al., 1989; Stebbing et 
al., 2000). Therapeutically effective antibodies, like Herceptin® or Rituxan®, 
have been shown to act through two different mechanisms, i.e. the 
engagement of the effector cells of the immune system as well as a direct 
cytotoxic, apoptosis inducing, effect (Baselga and Albanell, 2001; 
Sliwkowski et al., 1999; Soderlind et al., 2000; Vitetta and Uhr, 1994). 
Multinational studies have employed Herceptin® in protocols of combined 
therapy, prolonging significantly the life span of the patients (Cobleigh et 
al., 1999; Shak, 1999; Slamon et al., 2001). 
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3. Objectives 
Members of the EGFR family of receptor tyrosine kinases have been 
frequently implicated as causal agents in manifestation and progression of 
human cancer. Currently, the ErbB1/EGFR and ErbB2/HER2 are 
successfully pursued as targets for anti-tumour therapy. In particular, 
ErbB2/HER2 has been  under rigorous investigation and the therapeutical 
antibody Herceptin® has emerged and has subsequently been approved 
for the treatment of metastatic breast cancer. 
In this thesis, we address the functional role and signalling mechanisms of 
the third member of the EGFR-family, HER3 in gliomas. Additionally, we 
also set out to clarify the role of PYK2 tyrosine phosphorylation in human 
glioma cell lines upon Heregulin stimulation. Finally, we explore the 
inhibitory potential of a monoclonal antibody against ErbB3/HER3 (α-
HER3ECD) on signal transduction processes in breast cancer cells and 
compare its effector functions with those of Herceptin®. 
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4. Methods 
4.1. Materials and general methods 
Media were purchased from Gibco, fetal bovine serum (FBS), horse serum 
and Collagen Type IV were from Sigma. Hybond ECL membranes and γ-
32P-ATP were purchased from Amersham, PP1, AG825, Wortmannin 
(WT), PD98059 (Alessi et al., 1995b) and Ionomycin (IONO) from 
Calbiochem  and Herceptin® (HC) from Roche. Antibodies raised against 
following proteins were used: PYK2 (polyclonal goat antibody N19, Santa 
Cruz, and polyclonal rabbit antibody (pAb) Upstate Biotechnology, Inc. 
(UBI)), ERK-2 (pAb C14, K23, Signal Transduction), SHC (pAb (Seedorf et 
al., 1994), mAb, Affiniti), ErbB2/HER2 (monoclonal mouse antibody (mAb) 
2-13D), ErbB3/HER3 (mAb 2F12 (IgG2aκ), UBI, mAb (IgG1) (α−HER3ECD), 
UBI), p85 (mAb UB93-3, UBI), GRB2 (mAb 2F12, UBI), VSV (mAb P5D4, 
Boehringer Mannheim), and phosphotyrosine (mAb 4G10, UBI). HRP-
coupled secondary antibodies were purchased from Biorad, flourochrome-
coupled secondary antibodies from Molecular Probes. Transwell 
chambers (0.3 cm2, 8 µm) were purchased from Costar. Growth Factor 
Reduced Matrigel (GFRM) was purchased from Collaborative Biomedical 
Products. Thin-layer Chromatography plates (Silica Gel 60) precoated with 
oxalate were from Merck. Cell lines HEK293, rat C6 and PC12 and human 
SF763, SF767, PhoenixA and MDA-MB-468 were obtained from ATCC 
and cultured according to the supplier`s protocol. The human cell line 
MCF-7ADR was obtained from DKFZ (Heidelberg) and cultured according 
to the suppliers’ protocols. Tetracyclin-inducible PC12 system stably 
expressing PYK2-KM (Tet-off) was described previously (Zwick et al., 
1999).
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4.2. Purification of recombinant proteins 
Recombinant human GST-α-HRG fusion protein (α-HRG), GST-PYK2-CT, 
GST-GRB2 and GST-c-Jun were produced in E. coli and purified as 
described (Wallasch et al., 1995) or according to the purification protocol 
for pGEX fusion proteins (Pharmacia). GST-HER2-KD was generated by 
using the pRK5 construct and amplifying the kinase domain of HER2 (a.a. 
726-1012 by PCR. GST-HER3-KD was generated by using the pcDNA3.1-
HER3 construct and amplifying the kinase domain of HER3 (a.a. 730-
1065) by PCR.The purified recombinant proteins were dialyzed overnight 
against PBS and 10% glycerol, aliquoted and stored at –80°C. 
 
4.3. Immunoflourescence studies and confocal 
microscopy 
Briefly, SF763 and SF767 (3x105 cells) were grown on coverslips and 
starved for 24 h. After stimulation with 5 µg ml-1 HRG for 20 min, cells 
were fixed with 3.7% formaldehyd and permeabilized with 0.2% saponin 
(Sigma) in 3% BSA (Sigma). Blocking was performed with 3% BSA for 1 h. 
PYK2 and ErbB3/HER3 proteins were labeled with the indicated primary 
antibodies and stained using a fluorochrome-coupled donkey anti-goat α-
488 secondary antibody for PYK2, and TRITC-coupled rabbit anti-mouse 
secondary antibody for ErbB3/HER3 (Molecular Probes). Confocal images 
were taken with an LSM 410 microscope using a 40¥/1.3 Neofluar 
objective (Zeiss). For the GFP fluorescence, the 488 nm argon-ion laser 
band was used for excitation together with a 510-525 nm band-pass 
emission filter; for TRITC, the 543 nm helium-neon-ion band and a 570 nm 
high-pass filter; and for DAPI, the 364 nm argon-ion band and a 400-435 
nm band-pass filter (Weber et al., 1999). 
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4.4. Plasmid constructs and site-directed 
mutagenesis 
pcDNA3.1-PYK2-VSV and pcDNA3.1-PYK2-KM-VSV constructs were 
generated using the pRK5 constructs and standard methods. PYK2-KM 
was generated as described (Zwick et al., 1999). GST-PYK2-CT was 
generated by using the pRK5 construct and amplifying the C-terminus of 
PYK2 by PCR (positions 716-1009). The fragment was subcloned into the 
procaryotic expression vector pGEX-5X1 (Pharmacia). Tyrosine to 
phenylalanine mutations in ErbB3/HER3 were performed using the 
pcDNA3.1-ErbB3/HER3 construct and the QuickChange site-directed 
mutagenesis kit (Stratagene) according to the manufacturers protocol. 
Correct incorporation of the mutations was verified by DNA sequencing. 
 
4.5. Transient overexpression of PYK2, PYK2-KM, 
ErbB2/HER2, ErbB2/HER2-KM, ErbB3/HER3, and 
ErbB3/HER3-KM proteins in eukaryotic cells 
The HEK293 cell system was used for transient protein expression. 
HEK293 cells were maintained in DMEM supplemented with 10% FCS, 
penicillin and streptomycin (100 IU ml-1) at 7.5% CO2 and 37˚C. 
Transfections were carried out using a modified calcium phosphate 
method (Chen and Okayama, 1987). Briefly, 3.5x105 cells were incubated 
overnight in 3 ml of growth medium. 1 µg of supercoiled DNA was mixed 
with 0.25 M CaCl2 solution in a final volume of 400 µl. The mixture was 
added to the same volume of 2x transfection buffer (50 mM BES, pH 6.95, 
280 mM NaCl, 1.5 mM Na2HPO4) and incubated for 15 min at room 
temperature before it was added dropwise to the cells. After incubation for 
12 h at 37˚C under 3% CO2, the medium was removed, cells were 
washed twice with PBS and were then starved for 24 h in DMEM 
supplemented with 0.1% FCS. 
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4.6. Western Immunoblotting I 
SF763, SF767 or transfected HEK293 cells were either left untreated or 
were pretreated with PP1 (10 µM), AG825 (10 µM), Wortmannin (WT) 
(100 nM) and PD98059 (25 µM) for 30-60 min following stimulation with 5 
µg ml-1 recombinant human α-HRG for 20 min or with 5 µM IONO for 5 
min at 37˚C. Upon α-HRG or IONO stimulation, the cells were lysed on ice 
in a lysis buffer (50 mM HEPES pH 7.5, containing 150 mM NaCl, 1 mM 
EDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 1 mM Sodiumflouride, 1 
mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 1 mM β-
glycerolphosphate, 10 mg ml-1 aprotinin). Crude lysates were centrifuged 
at 12500 g for 20 min at 4˚C. For immunoprecipitations, the appropriate 
antiserum and 30 µl of protein A-Sepharose (Pharmacia) was added to the 
cleared lysate and incubated for 3 h at 4˚C. Immunoprecipitates were 
washed with a washing buffer (20 mM HEPES pH 7.5, containing 150 mM 
NaCl, 1 mM EDTA, 1 mM Sodiumflouride 10% (v/v) glycerol, 1% (v/v) 
Triton X-100). Sample buffer containing SDS and 2-mercaptoethanol was 
added and the samples were denaturated by heating at 95˚C for 4 min. 
Proteins were fractionated by SDS-PAGE and electrophoretically 
transferred to nitrocellulose filters. For immunoblot analysis, nitrocellulose 
filters were first incubated with mouse monoclonal or rabbit polyclonal 
primary antibodies for 3 h at 4˚C. Next, a HRP-coupled goat anti-mouse or 
goat anti-rabbit secondary antibody  was added (Biorad), followed by an 
enhanced chemoluminescence (ECL) substrate  reaction (Amersham). 
The substrate reaction was detected on Kodak X-Omat film. Filters that 
were used more than once with different antibodies were stripped 
according to the manufacturer's protocol, blocked and reprobed.
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4.7. Western Immunoblotting II 
MCF-7ADR and MDA-MB-468 cells were either left untreated or were 
pretreated with Herceptin (HC) (10 µg/ml), α-HER3ECD (10 µg/ml) and 
Wortmannin (WT) (100 nM) for 30-60 min following stimulation with 5 µg 
ml-1 recombinant human HRG for 5 min at 37˚C. Upon HRG stimulation, 
the cells were lysed on ice in a lysis buffer (50 mM HEPES pH 7.5, 
containing 150 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton 
X-100, 1 mM Sodiumflouride, 1 mM phenylmethylsulfonyl fluoride, 1 mM 
sodium orthovanadate, 1 mM β-glycerolphosphate, 10 mg ml-1 aprotinin). 
Crude lysates were centrifuged at 12500 g for 20 min at 4˚C. For 
immunoprecipitations, the appropriate antibody and 30 µl of protein A-
Sepharose (Pharmacia) were added to the cleared lysate and incubated 
for 3 h at 4˚C. Immunoprecipitates were washed with a washing buffer (20 
mM HEPES pH 7.5, containing 150 mM NaCl, 1 mM EDTA, 1 mM 
Sodiumflouride 10% (v/v) glycerol, 1% (v/v) Triton X-100). Sample buffer 
containing SDS and 2-mercaptoethanol was added and the samples were 
denaturated by heating at 95˚C for 4 min. 
Proteins were fractionated by SDS-PAGE and electrophoretically 
transferred to nitrocellulose filters. For immunoblot analysis, nitrocellulose 
filters were first incubated with mouse monoclonal or rabbit polyclonal 
primary antibodies for 3 h at 4˚C. Next, a HRP-coupled goat anti-mouse or 
goat anti-rabbit secondary antibody  was added, followed by an enhanced 
chemiluminescence (ECL) substrate reaction (Amersham). The substrate 
reaction was detected on Kodak X-Omat film. Filters that were used more 
than once with different antibodies were stripped according to the 
manufacturer's protocol, blocked and reprobed. 
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4.8. Generation of recombinant retroviruses and 
retrovirus-mediated gene transfer 
Briefly, pLXSN-PYK2 and pLXSN-PYK2-KM were generated by cloning an 
EcoRI-XhoI fragment from pRK5 carrying the cDNAs of PYK2-WT and 
kinase-inactive PYK2, K457M (PYK2-KM), respectively, into pLXSN. 
Amphotrophic virus titer, which was generated by transient transfection of 
retrovirus expression plasmids into the virus producer cell line PhoenixA 
(ATCC), was determined by infecting NIH-3T3 cells with serial dilutions of 
retrovirus-containing, cell-free PhoenixA supernatants and counting the 
number of G418-resistant colonies. The titers were approximately 1x106 
cfu ml-1 both for PYK2 and PYK2-KM virus supernatants. Subconfluent C6, 
SF763 and SF767 cells (9x105 cells) were incubated with supernatants of 
cells releasing high titers of pLXSN-PYK2 or pLXSN-PYK2-KM viruses 
(1x106 G418 cfu ml-1) for 24 h in the presence of Polybrene (4 mg ml-1, 
Aldrich). 
 
4.9. Cell surface biotinylation 
Monolayers of cells grown in 10-cm dishes were washed three times with 
ice-cold phosphate-buffered saline and then incubated with 0.5 mg/ml of a 
water-soluble Biotin-X-NHS (Calbiochem) dissolved in borate buffer 
(10 mM boric acid, 150 mM NaCl, pH 8.0) for 45 min at 4 °C. Coupling of 
biotin was blocked by extensive washes with a solution of 15 mM glycine 
in phosphate-buffered saline. Cells were then either treated with HRG 
(5 µg/ml) or with α-HER3ECD antibody for different time intervals at 37 °C. 
To evaluate the amounts of cell surface receptors, the cells were 
subjected to immunoprecipitation and gel electrophoresis. Visualization of 
the biotinylated proteins was performed by probing the nitrocellulose 
membranes with horseradish peroxidase-conjugated streptavidin 
(Amersham Pharmacia Biotech) and developed with an enhanced 
chemiluminescence reagent (Amersham Pharmacia Biotech). 
 
  
 
Methods  31 
4.10. In vitro-Kinase Assays 
4.10.1. ErbB3/HER3-Kinase Assay 
HER3 kinase assays were performed using either HER2 or HER3 
immunoprecipitates or 500 ng recombinant GST-HER2-KD GST-HER3-
KD. Cultured cells were lysed on ice in a lysis buffer (50 mM HEPES pH 
7.5, containing 150 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol, 1% (v/v) 
Triton X-100, 1 mM Sodiumflouride, 1 mM phenylmethylsulfonyl fluoride, 1 
mM sodium orthovanadate, 1 mM β-glycerolphosphate, 10 mg ml-1 
aprotinin). Crude lysates were centrifuged at 12500 g for 20 min at 4˚C. 
Endogenous ErbB3/HER3 is immunoprecipitated from the supernatants (2 
mg of protein) by incubation for 3.5 h with primary ErbB3/HER3 antibody 
(mAb 2F12, UBI) prebound to protein A beads. The pellets are washed 
twice with lysis buffer and thrice with a kinase buffer composed of 25mM 
HEPES (pH 7.5), 20 mM β–glycerophosphate, 7.5 mM MgCl2, 7.5 mM 
MnCl2, 1 mM DTT, and 0.1 mM sodium orthovanadate. Before kinase 
reaction was started immunoprecipitates or GST-fusions were 
equiliberated by adding 30 µl kinase reaction buffer including 10 µg GST-
PYK2-CT or MBP for 2 minutes at 30 °C. Kinase reaction was started by 
adding 10 µM ATP (including 10 µCi γ-32P-ATP), incubated for 30 minutes 
at 30°C and by adding 30 µl Lämmli-buffer. The kinase reactions are 
initiated by addition of 10 µCi of [γ-32P]-ATP, 15 µM “cold” ATP, and 5 µg 
of GST-PYK2-CT. The reaction mixture in a final volume of 40 µl is 
incubated at 30°C for 30 min and the reaction is terminated by addition of 
sample buffer containing SDS and 2-mercaptoethanol and the samples 
were denaturated by heating at 95˚C for 4 min. The reaction products are 
separated by electrophoresis on SDS-10% (w/v) polyacrylamide gels, and 
the gels either stained with Coomassie (G250) or blotted on a nylon 
membrane and the 32P-labeled proteins visualized by autoradiography. To 
determine equal protein loading, the membrane is stripped and reprobed 
with an specific anti-ErbB3/HER3 antibody.  
  
 
Methods  32 
4.10.2. MAPK Assay 
Cultured cells were lysed on ice in a lysis buffer (50 mM HEPES pH 7.5, 
containing 150 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton 
X-100, 1 mM Sodiumflouride, 1 mM phenylmethylsulfonyl fluoride, 1 mM 
sodium orthovanadate, 1 mM β-glycerolphosphate, 10 mg ml-1 aprotinin). 
Crude lysates were centrifuged at 12500 g for 20 min at 4˚C. Endogenous 
ERK-2 is immunoprecipitated from the supernatants (150 µg of protein) by 
incubation for 1.5 h with primary ERK-2 antibody (pAb K-23, SC) prebound 
to protein A beads. The pellets are washed twice with lysis buffer and 
twice with a kinase buffer composed of 25mM HEPES (pH 7.5), 20 mM β–
glycerophosphate, 20 mM PNPP, 20 mM MgCl2, 2 mM DTT, and 0.1 mM 
sodium orthovanadate. The kinase reactions are initiated by addition of 1 
µCi of [γ-32P]-ATP, 15 µM “cold” ATP, and 2 µg of myelin basic protein 
(MBP). The reaction mixture in a final volume of 40 µl is incubated at 30°C 
for 20 min and the reaction is terminated by addition of sample buffer 
containing SDS and 2-mercaptoethanol and the samples were 
denaturated by heating at 95˚C for 4 min. The reaction products are 
separated by electrophoresis on SDS-12.5% (w/v) polyacrylamide gels, 
blotted on a nylon membrane and the 32P-labeled proteins are visualized 
by autoradiography. To determine equal protein loading, the membrane is 
stripped and reprobed with an specific anti-ERK-2 antibody.  
 
4.10.3. JNK Assay 
Cultured cells are lysed in lysis buffer containing 20 mM Tris (ph 7.6), 
0.5% (v/v) Nonidet P-40 (NP-40), 250 mM NaCl, 3 mM EDTA, 1 mM 
dithiothreitol (DTT), 0.5 mM phenymethylsulfonyl fluoride (PMSF), 20 mM 
β–glycerophosphate, 1 mm sodium orthovanadate, and leupeptin (1µg/ml). 
The lysates are cleared by centrifugation at 15,000g for 15 min at 4°C. 
Endogenous JNK1 is immunoprecipitated from the supernatants (300 µg 
of protein) by incubation for 3 h with primary antibody JNK-1 (pAB, C-17 
SC) prebound to protein A beads. The pellets are washed twice with lysis 
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buffer and twice with a kinase buffer composed of 25mM HEPES (pH 7.5), 
20 mM –glycerophosphate, 20 mM PNPP, 20 mM MgCl2, 2 mM DTT, and 
0.1 mM sodium orthovanadate. The kinase reactions are initiated by 
addition of 5 µCi of [γ-32P]-ATP, 20 µM “cold” ATP, and 1 µg of glutathione 
S-transferase (GST)-c-jun (a.a. 1-79). The reaction mixture in a final 
volume of 25 µl is incubated at 30°C for 30 min and the reaction is 
terminated by addition of sodium docecyl sulfate (SDS) sample buffer and 
boiled for 5 min in tightly capped tubes. The reaction products are 
separated by electrophoresis on SDS-12.5% (w/v) polyacrylamide gels, 
blotted on a nylon membrane and the 32P-labeled proteins are visualized 
by autoradiography. To determine equal protein loading, the membrane is 
stripped and reprobed with an specific anti-JNK-1 antibody (Sudo and 
Karin, 2000).  
 
4.10.4. PI3-K Assay  
Briefly, tyrosine phosphorylated proteins were precipitated from HRG-
treated or untreated cells as described above. The immunoprecipitates 
were washed four times with 1 ml of the following buffer: 50 mM HEPES 
pH 7.5, 150 mM NaCl, 0.5 mM EGTA, 10% (v/v) glycerol, 0.2 mM sodium 
orthovanadate. After the last wash 40 µl aliquots of a master mix 
consisting of 10 µl 5X buffer (100 mM Tris-HCl pH 7.5, 500 mM NaCl, 25 
mM Mg(CH3COO)2, 25 mM MnCl2, 2.5 mM EGTA), 10 µl 
phosphatidylinositol + phosphatidylserine (0.5 mg/ml each in 20 mM 
HEPES, pH 7.5), 5 µl 0.2 mM ATP, 5 µl [γ-32P]-(10 µCi per sample) ATP 
solution and 5 µl H2O were added to the immunoprecipitates and the 
kinase reaction was stopped after incubation at 30°C for 30 min by the 
addition of 100 µl of 1 M HCl and 100 µl of methanol-chloroform [1:1 (v/v) 
mixture]. The lipid-containing organic phase was resolved on oxalate-
coated, thin-layer chromatography plates (Silica Gel 60; Merck) developed 
in chloroform:methanol:water:glacial acetic acid:acetone (40:13:7:12:15 
v/v). The plates were then dried and exposed for autoradiography and/or 
phosphoimager (Fuji) analysis (Alessi et al., 1995a; Morgan et al., 1990). 
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4.11. Proliferation Assay 
Proliferation was measured performing a BrdU-Incorporation assay 
(Roche) according to the manufacturers` protocol. 
 
4.12. Chemotaxis Assays 
4.12.1. Migration Assay 
Migration assay (Chemotaxis) was performed as follows: briefly, 2x105 
cells were plated on transwell chambers precoated with 4 µg Collagen 
Type IV. Conditioned NIH-3T3 medium was used as a chemoattractant 
(Albini et al., 1987). Following 16 h of incubation, non-migrating cells were 
removed with cotton swabs, whereas invading cells were fixed, stained 
with Crystal violet and counted under bright-field illumination using an 
Axiovert135 inverted microscope (Zeiss). Counts from 4 filters for each 
strain were pooled and compared among different strains using ANOVA. 
 
4.12.2. Tumor invasion Assay 
Tumor invasion assay was performed as described previously (Albini et 
al., 1987). Briefly, 3x105 cells were plated on transwell chambers 
precoated with 100 µg GFRM. Conditioned NIH-3T3 medium was used as 
a chemoattractant. Cells were stimulated with 5 µgml α-HRG during the 
experiment. Following 16 h of incubation, non-invading cells were 
removed with cotton swabs, whereas invading cells were fixed, stained 
with Crystal violet and counted under bright-field illumination using an 
Axiovert135 inverted microscope (Zeiss). Counts from 4 filters for each 
strain were pooled and compared among different strains using the two-
tailed t-test. 
  
 
Results  35 
5. Results 
5.1. Tyrosine-phosphorylation of PYK2 is dependent 
on ErbB2/HER2 and ErbB3/HER3 
PYK2 gets tyrosine-phosphorylated in the human glioma cell line SF767 
upon stimulation by α-HRG (Fig. 8a). In order to evaluate the mechanism 
of HRG-induced PYK2 tyrosine-phosphorylation, we inhibited two 
candidate protein tyrosine kinases, src and ErbB2/HER2, since it had 
been reported that src kinase associates with ErbB2/HER2 after HRG-
stimulation and phosphorylates PYK2 upon GPCR stimulation (Dikic et al., 
1996). Treatment of cells with the src inhibitor PP1 prior to HRG 
stimulation had no effect on PYK2 phosphorylation on tyrosines indicating 
that src does not mediate PYK2 tyrosine-phosphorylation after HRG 
treatment. In contrast, stimulation of SF767 cells by Ionomycin, which 
leads to an influx of Ca2+-ions as in the case of GPCR stimulation (Zwick 
et al., 1999), induces tyrosine-phosphorylation of PYK2 that is dependent 
on src activity (Fig. 8a, left vs. right panel, lanes 3 and 4). 
 
 
 
Fig. 8a: Effects of a c-src inhibitor PP1 on PYK2 tyrosine phosphorylation. Tyrosine 
phosphorylation of PYK2 is independent of c-src upon α-HRG stimulation, in contrast to 
IONO stimulation. SF767 gliomas were pretreated with 5 µM PP1 for 30 minutes and 
stimulated either with 5 µg ml-1 Heregulin (α-HRG, left panel) or 5 µM Ionomycin (IONO, 
right panel) for 20 min and 5 min, respectively. Tyrosine phosphorylation level was 
analysed by western blotting (WB) with monoclonal anti-phosphotyrosine antibody (α-PY) 
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(a, upper panel). Equal loading of proteins was checked by reblotting with α-PYK2 (a, 
lower panel). Unstimulated cells are indicated by NS. 
 
It has been reported that in the breast carcinoma cell line MDA-MB-435 
HRG-induced activation of ErbB2/HER2, which is mediated by 
heterodimerization between ErbB2/HER2 and ErbB3/HER3, leads to 
tyrosine-phosphorylation of PYK2 (Zrihan-Licht et al., 2000). As shown in 
figure 8b, in SF767 glioma cells a tyrosine phosphorylated protein of 
Mr=113 kDa, which coprecipitates with ErbB3/HER3 prior to stimulation 
with HRG was identified as PYK2 (Fig. 8b, upper and middle panels, lanes 
5-8). In contrast, under the same conditions precipitation of ErbB2/HER2 
reveals no association with PYK2 (Fig. 8b, upper and lower panel, lanes 1-
4). Upon HRG-stimulation tyrosine-phosphorylation of PYK2 increases 
(Fig. 8b, upper panel, lanes 5 and 7), but is attenuated in the presence of 
the ErbB2/HER2 inhibitor AG825 (Fig. 8b, upper panel, lanes 6 and 8), 
indicating that tyrosine-phosphorylation of PYK2 is dependent on 
ErbB2/HER2 kinase activity. The amount of PYK2 that coprecipitates with 
ErbB3/HER3 is not elevated by HRG-stimulation (Fig. 8b, middle panel, 
lanes 5 and 7), but decreases after addition of AG825 (Fig. 8b, middle 
panel, lanes 6 and 8). Tyrosine-phosphorylation of PYK2 was, however, 
attenuated in the presence of the ErbB2/HER2 inhibitor AG825 (Fig. 8b, 
lanes 9-12). Precipitation of PYK2 under the same conditions showed a 
weak but reproducibly specific association with ErbB3/HER3 (Fig. 8b, 
lanes 9-12), in a clear contrast to ErbB2/HER2, which showed no 
coprecipitation. These results suggest a constitutive association of PYK2 
with ErbB3/HER3, which is dependent on ErbB2/HER2 kinase activity. 
The same results were also obtained in the glioma cell line SF763 (data 
not shown), and suggest a constitutive association of PYK2 with 
ErbB3/HER3, which is ErbB2/HER2 kinase dependent. 
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Fig. 8b: Effects of a ErbB2/HER2 inhibitor AG825 on PYK2 tyrosine 
phosphorylation. PYK2 coprecipitation with ErbB3/HER3 depends on the ErbB2/HER2 
kinase activity, and tyrosine phosphorylation of PYK2 is proportional to its binding to 
ErbB3/HER3. SF767 gliomas were pretreated with 10 µM AG825 for 1 hour and 
stimulated with 5 µg ml-1 Heregulin for 20 min (α-HRG). Cell lysates were subjected to 
immunoprecipitation (IP) using polyclonal anti-PYK2 (α-PYK2) or monoclonal anti-
ErbB3/HER3 (α-ErbB3/HER3) antibodies. Tyrosine phosphorylation level was analysed 
by western blotting (WB) with monoclonal anti-phosphotyrosine antibody (α-PY) (b, upper 
panel). Equal loading of proteins was checked by reblotting with α-PYK2, α-ErbB3/HER3 
and α-ErbB2/HER2 antibodies, respectively (b, upper middle, middle and lower panels). 
PYK2 coprecipitating with ErbB3/HER3 was detected by probing the membrane with α-
PYK2 antibody (b, lower panel, lanes 5-8). ErbB3/HER3 coprecipitating with PYK2 was 
detected by probing the membrane with α-ErbB3/HER3 antibody (b, middle panel, lanes 
9-12). Unstimulated cells are indicated by NS. 
 
  
 
Results  38 
To provide further support for the PYK2/ErbB3/HER3 interaction, we 
performed immunoflourescense studies in SF763 and SF767 cell lines 
using a laser scanning confocal microscope (Fig. 9). As shown in figure 9, 
in both unstimulated and HRG-stimulated SF763 and SF767 cells, PYK2 
is predominantly localized to the perinuclear cytoplasm in a punctuated 
pattern, which is predominantly coincident with that of ErbB3/HER3 as 
demonstrated by image overlay. Thus, biochemical as well as cell 
biological immunofluorescense analysis supports the conclusion that 
PYK2 and ErbB3/HER3 are constitutively associated in glioma cells. 
 
 
 
Fig. 9: Localization of PYK2 and ErbB3/HER3 in SF763 and SF767 glioma cell lines. 
a, b, In SF767 (a) and in SF763 cells (b), PYK2 shows a punctated distribution 
throughout the cytoplasm, and is enriched in the perinuclear region and in some 
prominent cell protrusions (green). ErbB3/HER3 (red) is largely colocalized, as shown by 
overlapping distributions of the two stains in most puncta (b, insets) and in larger 
aggregates (yellow). Colocalization is independent of stimulation by α-HRG. Cells were 
fixed and immunostained against PYK2 (green) and ErbB3/HER3 (red), either 
unstimulated (NS) or following stimulation with 5 µg ml-1 Heregulin for 20 min (α-HRG). 
Optical sections obtained by confocal laser scanning microscopy are shown. Scale bar 
represents 10 µm. 
  
 
Results  39 
5.2. PYK2 associates with the intracellular region of 
ErbB3/HER3  
To investigate in detail how tyrosine-phosphorylation of PYK2 depends on 
binding to ErbB3/HER3 we used an ectopic overexpression system. 
HEK293 fibroblasts were used to express either wild-type ErbB2/HER2, 
ErbB3/HER3 and PYK2 or dominant-negative mutant constructs 
ErbB2/HER2-KM, ErbB3/HER3-KM and PYK2-KM, where the lysine 
critical for ATP-binding was exchanged with alanine, rendering the kinase 
inactive. Tyrosine-phosphorylation of PYK2 was elevated upon HRG-
stimulation of cells expressing all the wild-type constructs (Fig. 10a, lanes 
1 and 2). However, in cells expressing ErbB3/HER3-KM (Fig. 10a, lanes 3 
and 4) or ErbB2/HER2-KM (Fig. 10a, lanes 5 and 6), HRG-stimulation 
failed to induce PYK2 tyrosine-phosphorylation. This observation is 
consistent with the data from glioma cell lines (Fig. 8b), where inhibition of 
ErbB2/HER2 abrogated PYK2 activation, but further implies that HRG-
induced PYK2 activation is dependent on functional kinase activities of 
both ErbB2/HER2 and ErbB3/HER3. 
 
 
 
Fig. 10a: Association of PYK2 with the C-terminal domain of ErbB3/HER3. a, b, c, 
HEK293 fibroblasts were transfected with combinations of wild-type proteins 
(ErbB2/HER2, ErbB3/HER3, PYK2) and their dominant-negative variants (ErbB2/HER2-
KM, ErbB3/HER3-KM, PYK2-KM). PYK2 was expressed tagged at its C-terminus with the 
vesicular somatitis virus glycoprotein (VSV). PYK2 tyrosine phosphorylation is dependent 
on functional ErbB2/HER2 and ErbB3/HER3 kinase activity. Cells were stimulated with 5 
µg ml-1 Heregulin for 20 min (α-HRG), lysed and subjected to immunoprecipitation with 
monoclonal anti-VSV antibody (α-VSV). Immunocomplexes were analysed by western 
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blotting (WB) with a monoclonal anti-phosphotyrosine antibody (α-PY, upper panel). 
Equal loading of proteins was determined by reblotting with α-VSV antibody (lower 
panel). 
 
Additionally, we used PYK2-KM to exclude a pronounced constitutive 
autophosphorylation of wild-type PYK2. Again, in cells expressing 
ErbB3/HER3-KM or ErbB2/HER2-KM, stimulation with HRG failed to 
induce PYK2 tyrosine-phosphorylation, strongly supporting our hypothesis 
that HRG-induced PYK2 activation is dependent on functional kinase 
activities of both ErbB2/HER2 and ErbB3/HER3 (Fig. 10b, lanes 5-8).  
 
 
 
Fig. 10b: Association of PYK2 with the C-terminal domain of ErbB3/HER3. HEK293 
fibroblasts were transfected with combinations of wild-type proteins (ErbB2/HER2, 
ErbB3/HER3, PYK2) and their dominant-negative variants (ErbB2/HER2-KM, 
ErbB3/HER3-KM). This experiment was performed in parallel to the experiment shown in 
Fig. 2a, using PYK2-WT instead of PYK2-KM. A prominent autophosphorylation of PYK2-
WT is shown.  
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Next we used a mutant of ErbB3/HER3 lacking the C-terminal 697 amino 
acids (ErbB3/HER3∆CT) to analyse the contribution of this domain to 
HRG-induced PYK2 tyrosine-phosphorylation (Fig. 10c). In PYK2 
immunocomplexes of control cells expressing ErbB2/HER2 and 
ErbB3/HER3, we observed a coprecipitated protein of Mr=180 kDa which 
was phosphorylated and shown to be ErbB3/HER3 (Fig. 10c, lanes 1 and 
2). The deletion mutant of ErbB3/HER3 abrogated tyrosine-
phosphorylation of PYK2 and also the coprecipitation of ErbB3/HER3, 
indicating that PYK2 associates with the C-terminal region of ErbB3/HER3 
(Fig. 10c, lanes 3 and 4). We also observed in cells expressing 
ErbB2/HER2 and ErbB3/HER3∆CT an HRG-independent increase in 
tyrosine phosphorylation and protein expression of PYK2. This 
observation can be interpreted in that way that high levels of PYK2 
expression leads to its constitutive tyrosine phosphorylation since 
overexpressed tyrosine kinases are capable to transphosphorylate each 
other through transient dimer formation even in the absence of a ligand. 
 
 
Fig. 10c: Association of PYK2 with the C-terminal domain of ErbB3/HER3. HEK293 
fibroblasts were transfected with wild-type ErbB2/HER2 and PYK2 combined with wild-
type ErbB3/HER3 or its truncated construct ErbB3/HER3∆CT. Coprecipitating 
ErbB3/HER3 is indicated by an arrow. PYK2 was expressed tagged at its C-terminus with 
the vesicular somatitis virus glycoprotein (VSV). Cells were stimulated with 5 µg ml-1 
Heregulin for 20 min (α-HRG), lysed and subjected to immunoprecipitation with 
monoclonal anti-VSV antibody (α-VSV). Immunocomplexes were analysed by western 
blotting (WB) with a monoclonal anti-phosphotyrosine antibody (α-PY, upper panel). 
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Equal loading of proteins was determined by reblotting with α-VSV antibody (lower 
panel). 
 
The intracellular domain of ErbB3/HER3 harbours 13 phosphorylation 
sites that are thought to become transphosphorylated by ErbB2/HER2 
after HRG-stimulation. Among these the tyrosines Y1035, Y1178, Y1203, 
Y1241, Y1257 and Y1270 are potential docking sites for the src-homology 
2 (SH2) domains of the regulatory subunit p85 of PI3-K (Hellyer et al., 
1998), whereas Y1309 is a binding site for SHC (Prigent and Gullick, 
1994). To identify the specific binding sites for PYK2 in the C-terminal 
domain of ErbB3/HER3, we used 13 add-back mutants, in which all 
tyrosine residues had been replaced by phenylalanines with the exception 
of one. We performed transfection experiments in HEK293 fibroblasts, 
using wildtype PYK2 and ErbB2/HER2, and single add-back mutants of 
ErbB3/HER3 (Fig. 10d). Using this approach, we identified three tyrosine 
residues Y1257, Y1270 and Y1288, which are critical for elevated PYK2 
tyrosine-phosphorylation upon HRG-stimulation (Fig. 10d, lanes 13-18) 
and its physical association with HER3 (Fig. 10e, lanes 5-10). Based on 
these observations we conclude that the HRG-induced stimulation of 
PYK2 tyrosine-phosphorylation depends on its binding to Y1257, Y1270 
and Y1288 in the C-terminal domain of ErbB3/HER3. 
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Fig. 10d: Association of PYK2 with the C-terminal domain of ErbB3/HER3. HEK293 
fibroblasts were transfected as indicated. PYK2 activation is dependent on Y1257, Y1270 
and Y1288 in the C-terminal domain of ErbB3/HER3. PYK2 was expressed tagged at its 
C-terminus with the vesicular somatitis virus glycoprotein (VSV). Cells were stimulated 
with 5 µg ml-1 Heregulin for 20 min (α-HRG), lysed and subjected to immunoprecipitation 
with monoclonal anti-VSV antibody (α-VSV). Immunocomplexes were analysed by 
western blotting (WB) with a monoclonal anti-phosphotyrosine antibody (α-PY, upper 
panel). Equal loading of proteins was determined by reblotting with α-VSV antibody 
(lower panel). 
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Fig. 10e: Association of PYK2 with the C-terminal domain of ErbB3/HER3. HEK293 
fibroblasts were transfected as indicated. PYK2 activation is dependent on Y1257, Y1270 
and Y1288 in the C-terminal domain of ErbB3/HER3. PYK2 was expressed tagged at its 
C-terminus with the vesicular somatitis virus glycoprotein (VSV). Cells were stimulated 
with 5 µg ml-1 Heregulin for 20 min (α-HRG), lysed and subjected to immunoprecipitation 
with monoclonal anti-VSV antibody (α-VSV). Immunocomplexes were analysed by 
western blotting (WB) with a monoclonal anti-phosphotyrosine antibody (α-PY, upper 
panel). Note that ovexposure was required to detect coprecipitated HER3 in PYK2-VSV 
immunoprecipitates. PYK2 activation is dependent on Y1257, Y1270 and Y1288 in the C-
terminal domain of HER3. Equal loading of proteins was determined by reblotting with α-
VSV antibody (lower panel). 
 
  
 
Results  45 
5.3. Tyrosine-phosphorylation of PYK2 is dependent 
on ErbB3/HER3 kinase activity 
Although ErbB3/HER3 can bind ATP and its analog TNP-ATP (Sierke et 
al., 1997), it is widely believed that its kinase is inactive (Guy et al., 1994). 
This is based on the fact that two tyrosine kinase consensus positions in 
ErbB3/HER3 differ from other members of this gene family and 
experimental data with HER3 protein that indicated much lower kinase 
activity than that of the EGFR (Sierke et al., 1997). To identify the kinase 
which is responsible for the PYK2 tyrosine-phosphorylation upon HRG-
stimulation, we conducted in vitro kinase assays with myelin basic protein 
(MBP) and a GST-fusion protein of the C-terminal region of PYK2 (GST-
PYK2-CT) as substrates, in either anti-ErbB2/HER2 or anti-ErbB3/HER3 
immunoprecipitates (Fig. 11a).  
Upon stimulation of SF767 cells either with HRG, or with Phorbol-12-
myristate-13-acetate (PMA), MBP became phosphorylated by HER2, but 
not by ErbB3/HER3 (Fig. 11a, white bars). Surprisingly, however, GST-
PYK2-CT became phosphorylated by ErbB3/HER3 in a HRG-stimulation-
dependent way, but not by ErbB2/HER2 (Fig. 11a, black bars). 
 
 
Fig. 11a: Phosphorylation of GST-PYK2-CT by ErbB3/HER3 upon HRG stimulation. 
a, b, SF767 gliomas were either stimulated with 5 µg ml-1 Heregulin for 20 min (α-HRG) 
or with 1 µM Phorbol-12-myristate-13-acetate for 10 min (PMA). PMA stimulation was 
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used as a negative control. Note that kinase activity of ErbB3/HER3 is under 1% of the 
corresponding HER2 activity when using MBP as a substrate, in contrast to GST-PYK2-
CT.  
 
As it has been shown that PI3-K binds to the cytoplasmic tail of 
ErbB3/HER3, we investigated a potential role of PI3-K in PYK2 
phosphorylation by precipitating either ErbB2/HER2 or ErbB3/HER3 in the 
presence or absence of the PI3-K-inhibitor Wortmannin (WT) (Fig. 11b). 
The results indicate that PI3-K is not involved in the direct phosphorylation 
of GST-PYK2-CT. Consistent with this finding, precipitation of PYK2 under 
the same experimental conditions showed that its elevated tyrosine-
phosphorylation upon HRG-stimulation is independent of PI3-K (data not 
shown). Taken together, these data suggest that the ErbB3/HER3 kinase 
is active and phosphorylates tyrosine residues in the C-terminal region of 
PYK2. 
 
 
 
Fig. 11b: Phosphorylation of GST-PYK2-CT by ErbB3/HER3 upon HRG stimulation. 
SF767 gliomas were either stimulated with 5 µg ml-1 Heregulin for 20 min (α-HRG) or 
were pretreated with 100 nM Wortmannin for 30 min (WT). Upon α-HRG stimulation, 
phosphorylation of GST-PYK2-CT by ErbB3/HER3 is upregulated, in contrast to 
ErbB2/HER2 activity. Influence of WT is negligible, thus excluding involvement of PI3-K in 
PYK2 phosphorylation. Phosphorylated GST-PYK2-CT is indicated by an arrow.  
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To verify that ErbB3/HER3 directly phosphorylates PYK2, we 
overexpressed ErbB2/HER2 and ErbB3/HER3 either separately, or 
together in combinations with dominant-negative mutants in HEK293 cells 
(Fig. 11c). Receptor-immunocomplexes were subjected to in vitro kinase 
assays and revealed that, after HRG-stimulation, GST-PYK2-CT is 
phosphorylated in ErbB3/HER3 but not in immunoprecipitates (Fig. 11c, 
upper panel, lanes 3, 4, 5 and 6 vs. lanes 1 and 2).  
 
 
 
Fig. 11c: Phosphorylation of GST-PYK2-CT by ErbB3/HER3 upon HRG stimulation.  
HEK293 fibroblasts were transfected with the combinations of wild-type proteins 
(ErbB2/HER2, ErbB3/HER3) and their dominant-negative variants (ErbB2/HER2-KM, 
ErbB3/HER3-KM) as indicated, and stimulated with 5 µg ml-1 Heregulin  for 20 min (α-
HRG). Only homodimers of ErbB3/HER3 and heterodimers of ErbB3/HER3 with 
ErbB2/HER2 induced an increased GST-PYK2-CT phosphorylation (c, upper panel). 
Heterodimerization of ErbB3/HER3 with  leads to a stronger phosphorylation of the 
substrate, indicating that ErbB2/HER2 is important for ErbB3/HER3 activation. 
Transphosphorylation of ErbB3/HER3 by ErbB2/HER2 was checked by probing the 
membrane with an anti-phosphotyrosine antibody α-PY (c, upper middle panel). 
Coprecipitation of ErbB2/HER2 with ErbB3/HER3 was excluded by probing the 
membrane with anti- antibody α- (c, lower middle panel). Equal loading of proteins was 
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checked by probing with anti-ErbB3/HER3 antibody (α-ErbB3/HER3) (c, lower panel). 
Phosphorylated GST-PYK2-CT is indicated by an arrow. 
 
 
Fig. 11d: Phosphorylation of GST-PYK2-CT by ErbB3/HER3 upon HRG stimulation. 
Quantification of the kinase activity shown in the upper panel of Fig. 11c. 
 
ErbB3/HER3 homodimers also phosphorylated GST-PYK2-CT, but to a 
lesser extent compared to transactivated ErbB3/HER3 (Fig. 11c, upper 
panel, lanes 3 and 4). To show that ErbB3/HER3 is transphosphorylated 
by  upon HRG-stimulation, we probed the blot with the monoclonal anti-
phosphotyrosine antibody 4G10 (Fig. 11c, middle upper panel). We also 
show that there was no significant coprecipitation of ErbB2/HER2 in the 
ErbB3/HER3 immunocomplex under our assay conditions, strongly 
suggesting that ErbB2/HER2 is not the kinase, which phosphorylates 
GST-PYK2-CT (Fig. 11c, middle lower panel). We conclude that 
ErbB3/HER3 directly phosphorylates PYK2 upon HRG-stimulation. 
Additionally, we determined on which amino acid residues the 
phosphorylation event of GST-PYK2-CT occurred. We detected 
phosphorylated tyrosine and serine residues but not threonine residues 
(Fig. 11e, compare upper middle panel with middle and lower panels). 
Phosphorylation of tyrosine residues was dependent on HRG stimulation, 
whereas phosphorylation of serine residues was constitutive and 
independent of HRG stimulation, suggesting that a serine kinase 
coprecipitated with HER3. The findings that the HER2 kinase is not able to 
phosphorylate GST-PYK2-CT in a HRG dependent manner, and that the 
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exchange of a single methionine to lysine in HER3 prevents GST-PYK2-
CT phosphorylation, clearly indicate that HER3 is an active kinase 
responsible for the phosphorylation of tyrosine residues in the C-terminal 
region of PYK2. 
 
 
 
Fig. 11e: Phosphorylation of GST-PYK2-CT on tyrosine and serine, but not on 
threoinine residues upon HRG stimulation. In order to elucidate the phosphorylation 
content of GST-PYK2-CT, the blot was probed either with phosphotyrosine (α-PY), 
phosphoserine (α-PS) or phosphothreonine (α-PT) antibody. GST-PYK2-CT becomes 
tyrosine phosphorylated upon HRG stimulation, whereas constitutive serine 
phosphorylation and no threonine phosphorylation, respectively, is detectable upon HRG 
stimulation. This is a representative kinase assay of the experiment shown in Fig. 11d. 
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5.4. In vitro phosphorylation of GST-PYK2-CT by 
recombinant purified GST-HER3-KD 
To exclude the possibility that an associating tyrosine kinase 
phosphorylates GST-PYK2-CT in our mammalian systems, we purified 
bacterially expressed recombinant GST-fusion proteins of the HER2 (GST-
HER2-KD) and HER3 (GST-HER3-KD) kinase domains. We performed in 
vitro kinase assays using either GST-HER2-KD, GST-HER3-KD or 
recombinant c-SRC as enzymes and GST-PYK2-CT as substrate (Fig. 
12a). While recombinant c-SRC showed the strongest phosphorylation of 
GST-PYK2-CT (Fig. 12a left panel, lane 1), we also observed significant 
phosphorylation of GST-PYK2-CT by GST-HER2-KD, as well as GST-
HER3-KD (Fig. 12a, left panel, compare lanes 2 and 3). To show 
specificity of the kinase reaction we repeated the experiment using MBP 
as substrate (Fig. 12b left panel). Again strong phosphorylation by c-SRC 
was observed (Fig. 12b, left panel, lane 1), a weaker one by GST-HER2-
KD, but no phosphorylation by GST-HER3-KD (Fig. 12b, left panel, 
compare lanes 2 and 3). This experiment clearly demonstrated that in a 
defined in vitro system HER3 has kinase activity and GST-PYK2-CT 
serves as substrate for the enzymatic function of HER3. It further confirms 
and substantiates the data obtained with intact SF767 and HEK293 cells. 
The fact that HER2 was able to phosphorylate GST-PYK2-CT in vitro, 
while this was not the case HRG-dependently in intact cells suggest the 
involvement of cellular parameters in substrate selection. 
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Fig. 12: GST-HER3-KD tyrosine phosphorylates GST-PYK2-CT. (a) Recombinant c-
SRC, and bacterially expressed GST-HER2-KD and GST-HER3-KD were used as 
enzymes and GST-PYK2-CT (a) as substrate. Coomassie-stained gels are shown to 
confirm equal protein loading (a, right panel). (b) The same experimental procedure was 
used as in (a), except that MBP was used as the substrate. Note that GST-HER3-KD 
phosphorylates GST-PYK2-CT stronger than GST-HER2-KD, whereas using MBP as 
substrate no phosphorylation of MBP over background occurred, demonstrating substrate 
specificity of HER3. 
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5.5. PYK2 amplifies the ErbB2/HER2-ErbB3/HER3 
mitogenic signal 
Upon stimulation of ErbB3/HER3 and ErbB2/HER2, PI3-K and SHC bind to 
the C-terminus of ErbB3/HER3 and mediate the transmission of a signal 
through the Ras/Raf pathway (Yarden and Sliwkowski, 2001). To test the 
influence of ErbB2/HER2 and PI3-K on MAPK activation, we exposed 
SF767 cells to respective inhibitors AG825 and Wortmannin (WT) prior to 
stimulation with HRG. Then we precipitated SHC or performed MAP-
kinase assays (Fig. 13a, b).  
 
 
 
Fig. 13a, b: PYK2 mediates a mitogenic response upon HRG stimulation. a, b, SF767 
gliomas were pretreated either with 10 µM AG825 for 1 hour or with 100 nM Wortmannin 
for 30 min (WT), and then stimulated with 5 µg ml-1 Heregulin for 20 min (α-HRG). 
Tyrosine phosphorylation of SHC was elevated by α-HRG and attenuated by 
pretreatment with AG825, but not fully abrogated (a). The same holds also for ERK-2 
activity, when cells were pretreated either with AG825 or with WT (b). Cell lysates were 
used for immunoprecipitation with polyclonal anti-SHC (α-SHC) (a), or polyclonal anti-
Erk-2 (α-ERK-2) antibodies (b). α-SHC-immunocomplexes were blotted with a 
monoclonal anti-phosphotyrosine antibody (α-PY) (a), whereas α-ERK-2 
immunocomplexes were subjected to MAP-kinase assays (b). Phosphorylated MBP is 
indicated by an arrow. Phosphorylated MBP is indicated by an arrow.  
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HRG-stimulated tyrosine-phosphorylation of SHC and ERK-2 activity was 
diminished, but not fully abrogated by inhibition of ErbB2/HER2 (Fig. 13a, 
13b, left panel). The analogous experiment using WT for inhibition of PI3-K 
revealed that ERK-2 activity was reduced by WT (Fig. 13b, right panel). 
These findings indicate that the HRG-induced MAPK signal only partially 
depends on ErbB2/HER2 and PI3-K. 
To characterize in more detail the role of PYK2 downstream of the 
ErbB2/HER2-ErbB3/HER3 signal, we used a tetracyclin-inducible system 
(Tet-off) in the pheochromocytoma cell line PC12 (Zwick et al., 1999). 
PC12 cells are rich in PYK2, so that in the presence of Tet only 
endogenous PYK2 is expressed, whereas Tet removal leads to 
overexpression of kinase-deficient dominant-negative PYK2 (PYK2-KM). 
We inhibited either ErbB2/HER2 or PI3-K with AG825 and WT, 
respectively, prior to stimulation with HRG, precipitated ERK-2 and 
subjected the immunocomplexes to MAP-kinase assays (Fig. 13c).  
 
 
Fig. 13c, d: PYK2 mediates a mitogenic response upon HRG stimulation. c, 
Tetracyclin-inducible pheochromocytoma PC12 cells, either stably expressing PYK2-KM 
(Tet-), or only endogenous PYK2 (Tet+), were pretreated either with 100 nm Wortmannin 
for 30 min (WT), or 10 µM AG825 for 1 hour prior to stimulation with 5 µg ml-1 Heregulin 
for 20 min (α-HRG). Basal ERK-2 activity is independent of ErbB2/HER2 and PI3-K, 
whereas the α-HRG-stimulated ERK-2 activity is dependent on ErbB2/HER2,PI3-K and 
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PYK2. Overexpression of PYK2-KM leads to a general attenuation of ERK-2 activity 
(compare Tet- with Tet+ bands). Equal loading of proteins was checked by probing with 
anti-ERK-2 antibody (α-ERK-2). Phosphorylated MBP is indicated by an arrow. d, 
Quantification of the ERK-2 kinase activity shown in Fig. 13c. 
 
Basal ERK-2 activity was not influenced by AG825 and WT, but was 
abrogated upon PYK2-KM expression. HRG-stimulated ERK-2 activity, 
however, was attenuated by the two inhibitors, and also abrogated by 
PYK2-KM expression. These findings are consistent with the results 
obtained in SF767 (Fig. 13b), and together indicate that the constitutive 
basal ERK-2 activity in both PC12 and SF767 glioma cells depends on 
PYK2, and is independent of ErbB2/HER2 and PI3-K, whereas further 
stimulation of ERK-2 by HRG requires ErbB2/HER2, PI3-K, and PYK2. 
 
5.6. Involvement of PYK2 in ErbB2/HER2-
ErbB3/HER3-mediated tumour invasion 
In addition to its role in cell proliferation and anti-apoptosis, an involvement 
of PI3-K in carcinoma invasion has recently been demonstrated (Shaw et 
al., 1997). We therefore investigated the potential of PYK2 and its 
dominant-negative mutant PYK2-KM to influence PI3-K activation upon 
HRG-stimulation. Using the Tet-off system in PC12 cells, we subjected cell 
lysates to PI3-K assays, where we observed PYK2-dependent PI3-K 
activation upon HRG-stimulation (Fig. 14, upper panel, lanes 1 vs. 2 with 7 
and 8). 
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Fig. 14: PYK2 enhances PI3-K activity upon HRG stimulation. a, Tetracyclin-inducible 
pheochromocytoma PC12 cells, either stably expressing PYK2-KM (Tet-) or only 
endogenous PYK2 (Tet+), were pretreated either with 100 nm Wortmannin for 30 min 
(WT), or 10 µM AG825 for 1 hour prior to stimulation with 5 µg ml-1 Heregulin for 20 min 
(α-HRG). Lysates were subjected to α-PY immunoprecipitation and PI3-K assays were 
performed (see Methods section). PI3-K activity is strongly dependent on PYK2 upon α-
HRG stimulation, and is diminished by AG825. Phosphorylated Phosphatidylinositol is 
indicated. b, Quantification of the PI3-K kinase activity shown in Fig. 14a. 
 
Inhibition of ErbB2/HER2 kinase activity did only partially abrogate PI3-K 
activity, indicating the involvement of a ErbB2/HER2-independent 
mechanism of PI3-K activation (Fig. 14, upper panel, lanes 8 and 12) and 
an important role of PYK2 in HRG induction of MAPK signalling and in PI3-
K activation. 
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Further experiments adressed the role of PYK2 in the invasive properties 
of glioma cells. Gliomas represent highly malignant brain tumours with a 
very poor prognosis (Berens and Giese, 1999). It has been shown that PI3-
K links α6β4-integrin signalling to invasive behaviour of breast tumour 
cells (Shaw et al., 1997). Furthermore, it has been reported that activation 
of MAPK through α6β4-integrin signalling is relevant to invasion, due to its 
importance in migration and its ability to phosphorylate myosin light chain 
kinase (Klemke et al., 1997). Using the C6 glioma cell line as a model 
system for tumour invasion (Kaye et al., 1986), we tested whether PYK2 
activity is required for this process and if so, by what mechanism. We used 
a recombinant retrovirus to transfer coding sequences for PYK2-KM into 
C6 glioma cells prior to stimulation with HRG. To ask whether the MAPK 
pathway plays a role in the process, we also pretreated the cells with the 
MEK1 inhibitor PD98059 (Fig. 15a).  
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Fig. 15a, b: PYK2-KM inhibits tumour invasion upon HRG stimulation. a, C6 gliomas 
were retrovirally infected with either a control vector pLXSN (mock), PYK2, dominant 
negative PYK2 mutant PYK2-KM, or pretreated with a MEK1 inhibitor PD98059 (25 µM) 
for 30 min, and tumour invasion assays were performed (see Methods section). b, 
Invasion is supressed to the same extent by PD98059 and by overexpression of PYK2-
KM (p>0.95). Representative bright-field micrographs of cells that migrated through the 8 
µm filters in 16 h are shown. Scale bars represent 100 µm (a). 
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MEK1-inhibition strongly attenuated invasiveness and a comparable 
abrogation of the invasive phenotype was observed upon infection of cells 
with PYK2-KM. The mitogenic signal of the ErbB2/HER2-ErbB3/HER3 
dimer seems to be downregulated by PYK2-KM, however, overexpression 
of PYK2 in C6 cells did not significantly enhance their invasive phenotype 
(Fig. 15b). Endogenous PYK2 expression in C6 cells is comparably 
weaker than in SF763 or SF767 cells (data not shown), but this does not 
seem to interfere with their invasive potency. We also tested glioma cell 
lines SF763 and SF767 in the tumour invasion assay, after viral infection 
with the PYK2-KM construct. Again, a strong inhibition of the invasive 
behaviour of tumour cells by PYK2-KM was observed (Fig. 15d). These 
results demonstrate that PYK2 can activate the MAPK pathway, which 
plays an important role in glioma invasion upon HRG-stimulation. 
 
 
 
Fig. 15c, d: PYK2-KM inhibits tumour invasion upon HRG stimulation. c, SF767 
gliomas were retrovirally infected with pLXSN or PYK2-KM. d, Tumor invasion is 
supressed by overexpresssion of PYK2-KM in SF767 (p<0.008), and also in SF763 cell 
line (p<0.005), as shown by using the same assay as in Fig 15a, b. Representative 
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bright-field micrographs of cells that migrated through the 8 µm filters in 16 h are shown. 
Scale bars represent 50 µm (c). 
 
In parallel we examined ERK-2 phosphorylation events and determined a 
decrease in ERK-2 phosphorylation by using either PD98059 or 
expressing PYK2-KM in both C6 and SF767 cell lines (Fig. 15e, f upper 
panel, compare lanes 6 and 7 with 5). These results indicate that PYK2 
activates the MAPK pathway, and thereby plays a critical role in HRG-
mediated glioma invasion. 
 
 
 
 
 
Fig. 15e, f: PYK2-KM inhibits ERK-2 activity in C6 and SF767 cells. (e) Whole cell 
lysates (WCL) of C6 glioma cells were prepared in parallel to the tumor invasion assay 
and the content of phosphorylated ERK-2 was assessed by probing with a specific 
phospho-ERK-2 antibody (upper panel). To confirm equal loading of proteins the blot was 
reprobed with a pan-ERK antibody. (f) The same experimental procedure was used as in 
(e) for SF767 cells. Phosphorylated ERK-2 is indicated by an arrow. Dominant-negative 
PYK2-KM abrogates ERK-2 activity to the same extent as MEK-1 inhibitor PD98059. 
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5.7. α-HER3ECD interferes with receptor tyrosine 
phosphorylation and dimerisation of ErbB3/HER3 
and ErbB2/HER2 
We have compared the effects of a monoclonal antibody against the 
extracellular domain of ErbB3/HER3 with those of the anti-ErbB2/HER2 
therapeutic monoclonal antibody Herceptin® (HC) on HRG-mediated 
signalling. The breast cancer cell lines MCF-7ADR and MDA-MB-468 were 
chosen as a model on the basis of their different ratios of 
ErbB2/HER2:ErbB3/HER3 and their inherent migratory properties, with 
MDA-MB-468 being the most invasive cell line. The ratios of 
ErbB2/HER2:ErbB3/HER3 were about 1:3 and 3:1 in MDA-MB-468 and 
MCF-7ADR respectively, based on cDNA array analysis data and western 
blot (E.H.v.d.H. unpublished observation). In order to assess the effect of 
α-HER3ECD in comparison to HC, the cells were pretreated with α-
HER3ECD or HC respectively prior to HRG stimulation. Receptor-
immunoprecipitation was then performed and the phosphotyrosine content 
of ErbB2/HER2 and ErbB3/HER3 analyzed by western blot with an anti-
phosphotyrosine (PY) antibody (Fig. 16).  
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Fig. 16a: α-HER3ECD interferes with receptor tyrosine phosphorylation and 
dimerisation of ErbB3/HER3 and ErbB2/HER2 in MCF-7ADR cells . a, Serum starved 
breast cancer cells MCF-7ADR were pretreated either with 50 µg/ml HC or 10 µg/ml α-
HER3ECD for 60 minutes. Cell stimulation was carried out for 5 min. with 5 µg ml-1 α-
Heregulin (HRG) for MCF-7ADR . Cell lysates were subjected to immunoprecipitation (IP) 
using monoclonal anti-ErbB2/HER2 (α-ErbB2/HER2) or monoclonal anti-ErbB3/HER3 (α-
ErbB3/HER3) antibodies. The level of tyrosine phosphorylation was analyzed by western 
blotting (WB) with a monoclonal anti-PY antibody (α-4G10) (upper panels). Reblotting 
with α-ErbB2/HER2 and α-ErbB3/HER3 antibodies shows equal protein loading (middle 
and bottom panels). Unstimulated cells are indicated by NS. Coprecipitating proteins are 
indicated by an arrow. 
 
 
 
Fig. 16b: α-HER3ECD interferes with receptor tyrosine phosphorylation and 
dimerisation of ErbB3/HER3 and ErbB2/HER2 in MDA-MB-468. b, Serum starved 
breast cancer cells MDA-MB-468 were pretreated either with 50 µg/ml HC or 10 µg/ml α-
HER3ECD for 60 minutes. Cell stimulation was carried out for 5 min. with 10 ng/ml β-
Heregulin for MDA-MB-468. Cell lysates were subjected to immunoprecipitation (IP) using 
monoclonal anti-ErbB2/HER2 (α-ErbB2/HER2) or monoclonal anti-ErbB3/HER3 (α-
ErbB3/HER3) antibodies. The level of tyrosine phosphorylation was analyzed by western 
blotting (WB) with a monoclonal anti-PY antibody (α-4G10) (upper panels). Reblotting 
with α-ErbB2/HER2 and α-ErbB3/HER3 antibodies shows equal protein loading (middle 
and bottom panels). Unstimulated cells are indicated by NS. Coprecipitating proteins are 
indicated by an arrow. 
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As shown in figure 16, pretreatment with α-HER3ECD substantially 
decreased the tyrosine phosphorylation level of ErbB3/HER3 and 
ErbB2/HER2 after α-HRG stimulation in MCF-7 (Fig. 16a); in MDA-MB-
468, where ErbB2/HER2 is more abundant than ErbB3/HER3, the tyrosine 
phosphorylation of ErbB2/HER2 was still reduced whilst, interestingly, an 
increase of ErbB3/HER3 tyrosine phosphorylation and of ErbB2/HER2-
ErbB3/HER3 association could be observed (Fig. 16b, lanes 6 and 12). In 
contrast, HC upregulated receptor tyrosyl-phosphorylation and promoted 
association of ErbB3/HER3 and ErbB2/HER2, independent of HRG 
stimulation, in both cell lines (Fig. 16a, b).  
 
5.8. α-HER3ECD decreases the phosphorylation of 
SHC and modifies the association of SHC and PI3-K 
with ErbB3/HER3 
We subsequently asked whether α-HER3ECD has an effect on the known 
substrates of ErbB3/HER3, namely SHC and PI3-K, which are effector 
proteins responsible for MAPK cascade activation and lipid signalling 
respectively (Wallasch et al., 1995; Yarden and Sliwkowski, 2001). To 
address this question, we immunoprecipitated SHC and the regulatory 
subunit of PI3-K, p85, under the experimental conditions described above 
and assessed the tyrosine phosphorylation of these effectors (Fig. 17).  
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Fig. 17a: α-HER3ECD decreases the phosphorylation of SHC and modifies the 
association of SHC and PI3-K with ErbB3/HER3 in MCF-7ADR cells. Serum starved 
breast cancer cells MCF-7ADR were pretreated and stimulated as described in figure 16. 
Cell lysates were either subjected to immunoprecipitation (IP) using monoclonal anti-
SHC2 (α-SHC2) or monoclonal anti-PI3-K (α-PI3-K) antibodies. Tyrosine phosphorylation 
levels were analyzed by western blotting (WB) with monoclonal anti-phosphotyrosine 
antibody (α-4G10) (a, upper panels). Reblots with α-SHC and α- PI3-K antibodies were 
performed as a control for protein loading (a, bottom panels). Coprecipitation of 
ErbB2/HER2 and ErbB3/HER3 with SHC or with PI3-K was detected by probing the 
membrane either with α-ErbB2/HER2 or α- ErbB3/HER3 antibody (a, middle panes). 
Unstimulated cells are indicated by NS. Coprecipitating proteins are indicated by an 
arrow. 
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Fig. 17b: α-HER3ECD decreases the phosphorylation of SHC and modifies the 
association of SHC and PI3-K with ErbB3/HER3 in MDA-MB-468 cells. Serum starved 
breast cancer cells MDA-MB-468 were pretreated and stimulated as described in figure 
16. Cell lysates were either subjected to immunoprecipitation (IP) using monoclonal anti-
SHC2 (α-SHC2) or monoclonal anti-PI3-K (α-PI3-K) antibodies. Tyrosine phosphorylation 
levels were analyzed by western blotting (WB) with monoclonal anti-phosphotyrosine 
antibody (α-4G10) (b, upper panels). Reblots with α-SHC and α- PI3-K antibodies were 
performed as a control for protein loading (b, bottom panels). Coprecipitation of 
ErbB2/HER2 and ErbB3/HER3 with SHC or with PI3-K was detected by probing the 
membrane either with α-ErbB2/HER2 or α- ErbB3/HER3 antibody (b, middle panes). 
Unstimulated cells are indicated by NS. Coprecipitating proteins are indicated by an 
arrow. 
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As shown in figure 17, α-HER3ECD significantly decreased the tyrosine 
phosphorylation of SHC (lower arrow) after HRG stimulation in the cell 
lines MCF-7ADR and MDA-MB-468 (Figure 17a, b compare lane 10 with 
12). Interestingly, the association of SHC with the tyrosine-phosphorylated 
receptors (upper arrow) was strongly inhibited in MCF-7ADR cells but not in 
MDA-MB-468. The immunoprecipitates of the regulatory subunit of PI3-K 
yielded similar results. The binding of tyrosine-phosphorylated 
ErbB3/HER3 to p85 was decreased in MCF-7ADR, while, interestingly, an 
increase was observed in MDA-MB-468 (Fig. 17a, b, lanes 4 and 6). HC 
enhanced binding of the effector proteins SHC and PI3-K in both cell lines 
(lane 5). These data show that α-HER3ECD interferes with SHC function by 
inhibiting its tyrosine phosphorylation. The association of SHC and PI3-K 
with ErbB3/HER3 is substantially modified by α-HER3ECD with respect to 
control treatment in both cell lines: in MCF-7ADR, where ErbB3/HER3 is 
more abundant than ErbB2/HER2, the association with the effectors is 
decreased while in MDA-MB-468, where ErbB3/HER3 is present in a lower 
relative amount than ErbB2/HER2, α-HER3ECD promotes the association 
of SHC and PI3-K both under resting and stimulated conditions. 
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5.9. α-HER3ECD decreases the phosphorylation of 
SHC and modifies the association of GRB2 with 
ErbB2/HER2 
Since SHC associates with the adaptor molecule GRB2 after HRG 
stimulation, we explored the effect of the reduced phosphorylation of SHC 
in MCF7 cells by measuring GRB2 binding (Fig. 18). Therefore we 
performed GST-pulldown assays in cells using GST-GRB2 fusions and the 
same experimental design as before.  
 
 
 
Fig. 18: α-HER3ECD decreases the phosphorylation of SHC and modifies the 
association of GRB2 with ErbB2/HER2. Serum starved breast cancer cells MCF-7ADR 
were pretreated and stimulated as described in figure 16. Cell lysates were subjected to a 
GST-GRB2 pulldown assay with 5µg recombinant GST-GRB2 protein coupled to 
Glutathione Sepharose. Tyrosine phosphorylation levels were analyzed by western 
blotting (WB) with monoclonal anti-phosphotyrosine antibody (α-4G10) (upper panels). 
Coprecipitation of ErbB2/HER2 and SHC with GST-GRB2 was detected by probing the 
membrane either with α-ErbB2/HER2 or α-SHC antibody (middle panes). Unstimulated 
cells are indicated by NS. Coprecipitating proteins are indicated by an arrow. 
 
  
 
Results  67 
Indeed, the reduced tyrosine phosphorylation of SHC observed in MCF-
7ADR resulted in a decreased binding of GRB2 to SHC (Fig. 18 bottom 
panel, compare lane 4 and 6), and a complete inhibition of its association 
with ErbB2/HER2 (Fig. 18 middle panel). 
 
5.10. α-HER3ECD inhibits JNK1 and PI3-K activity 
Given the qualitatively different signalling interference caused by α-
HER3ECD in the two cell lines, we asked whether the downstream effects 
of the antibody would also be different. The adaptor protein SHC regulates 
MAPK signalling pathways downstream of growth-factor receptors, 
activating JNK and ERK-2, respectively (Hashimoto et al., 1999; Vijapurkar 
et al., 1998). To investigate the effect of α-HER3ECD on MAP kinase 
signalling we performed kinase assays under the same experimental 
conditions in MCF-7ADR and MDA-MB-468 (Fig. 19).  
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Fig. 19a: α-HER3ECD inhibits JNK1 and PI3-K activity in MCF-7ADR cells. a, Serum 
starved breast cancer cells MCF-7ADR were pretreated either with 50 µg/ml HC or 10 
µg/ml α-HER3ECD for 60 minutes or with 100 nM/ml Wortmannin (WT) for 30 minutes and 
stimulated as described in figure 16. Cell lysates were either used for 
immunoprecipitation with polyclonal anti-JNK-1 (α-JNK-1) antibody or monoclonal α-
4G10 and PI3-K assays were performed (see Methods section). Whole cell lysates (WCL) 
were additionally probed with α-PY antibody to confirm effect of α-HER3ECD on SHC 
tyrosine phosphorylation and after stripping reprobed with α-SHC antibody to determine 
equal loading of proteins (a, middle and upper lower panels). α-JNK-1 immunocomplexes 
were subjected to JNK-kinase assays (a, upper panels). Phosphorylated c-jun is 
indicated by an arrow. An anti-JNK-1 antibody (α-JNK-1) was used to confirm equal 
protein loading. PI3-K activity is strongly diminished after α-HER3ECD pretreatment, due to 
the inhibition of PI3-K binding to ErbB3/HER3 (a, lower panels). Phosphorylated 
Phosphatidylinositol is indicated by an arrow. 
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Fig. 19b: α-HER3ECD inhibits JNK1 and PI3-K activity. Serum starved breast cancer 
cells MDA-MB-468 were pretreated either with 50 µg/ml HC or 10 µg/ml α-HER3ECD for 
60 minutes or with 100 nM/ml Wortmannin (WT) for 30 minutes and stimulated as 
described in figure 16. Cell lysates were either used for immunoprecipitation with 
polyclonal anti-JNK-1 (α-JNK-1) antibody or monoclonal α-4G10 and PI3-K assays were 
performed (see Methods section). Whole cell lysates (WCL) were additionally probed with 
α-PY antibody to confirm effect of α-HER3ECD on SHC tyrosine phosphorylation and after 
stripping reprobed with α-SHC antibody to determine equal loading of proteins (b, middle 
and upper lower panels). α-JNK-1 immunocomplexes were subjected to JNK-kinase 
assays (b, upper panels). Phosphorylated c-jun is indicated by an arrow. An anti-JNK-1 
antibody (α-JNK-1) was used to confirm equal protein loading. PI3-K activity is strongly 
diminished after α-HER3ECD pretreatment, due to the inhibition of PI3-K binding to 
ErbB3/HER3 (b, lower panels). Phosphorylated Phosphatidylinositol is indicated by an 
arrow. 
 
The pretreatment with α-HER3ECD determined a strong decrease of JNK 
activity in both cell lines (Fig.19a, b, compare lane 5 and 8); strikingly, the 
inhibitory effect of α-HER3ECD on JNK kinase activity was even stronger in 
MDA-MB-468 than in MCF-7ADR. HC, on the other hand, only reduced JNK 
activity in MCF-7ADR (Fig. 19a). ERK-2 activity was significantly decreased 
after pretreatment with α-HER3ECD, whereas HC had no effect (data not 
shown). Since an involvement of PI3-K in carcinoma invasion has recently 
been demonstrated (Shaw et al., 1997), we investigated the inhibitory 
properties of α-HER3ECD on PI3-K activity (Fig. 19a, b, bottom panels). In 
both cell lines α-HER3ECD resulted in a strong decrease of PI3-K activity 
upon HRG stimulation (Fig. 19a, b). In MDA-MB-468 HC exerted an even 
greater inhibitory effect on PI3-K activity than α-HER3ECD, which could be 
due to the threefold higher expression of ErbB2/HER2 than in MCF-7ADR. 
Wortmannin (WT), a widely used inhibitor of PI3K, was also used as a 
control pretreatment (lanes 2,6). Taken together, these results have a 
potential therapeutic significance, because they show that α-HER3ECD 
differentially modifies early signalling events (i.e. receptor phosphorylation, 
PI3-K and SHC association) according to the ErbB2/HER2:ErbB3/HER3 
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ratio, but invariably decreases the activity of downstream effectors 
regardless of the ErbB2/HER2:ErbB3/HER3 ratio. 
 
5.11. Effect of α-HER3ECD and Herceptin® on the 
endocytosis of ErbB3/HER3 and ErbB2/HER2 after 
HRG stimulation 
We then tried to dissect the molecular mechanisms leading to α-HER3ECD-
induced inhibition of ErbB3/HER3 tyrosine phosphorylation. It is known 
that ErbB2/HER2 and ErbB3/HER3 are endocytosed and recycled after 
HRG stimulation (Yarden and Sliwkowski, 2001). To assess whether α-
HER3ECD interferes with receptor recycling, we determined the surface 
expression of ErbB3/HER3 after incubation with the antibody for different 
time periods and subsequent stimulation with HRG for 5 minutes. 
ErbB3/HER3 was immunoprecipitated after biotinylation of membrane 
proteins and the corresponding phosphotyrosine content assessed by 
western blot in whole cell lysates (Fig. 20).  
 
 
 
Fig. 20a: Effect of α-HER3ECD and HRG on the endocytosis of ErbB3/HER3. Serum 
starved MCF-7ADR cells were incubated at 4°C with 10 µg/ml α-HER3ECD or with 5 µg ml-1 
α-Heregulin (HRG) for 1 h, then washed two times with PBS and incubated at 37°C for 
the indicated timepoints. At the end of incubation, cells were biotinylated and lysed (see 
Method section). Cell lysates were subjected to immunoprecipitation (IP) using 
monoclonal monoclonal anti-ErbB3/HER3 (α-ErbB3/HER3) antibodies (a, upper panel). 
Tyrosine phosphorylation level of whole cell lysates (WCL) was analyzed by western 
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blotting (WB) with monoclonal anti-phosphotyrosine antibody (α-4G10) (a, lower panels). 
NS, unstimulated cells. 
 
As shown in Fig. 20a (upper panel), α-HER3ECD caused a long-lasting 
decrease in the surface expression of ErbB3/HER3; the activation state of 
the receptor after HRG stimulation was, at all pretreatment time points, 
indistinguishable from that of control untreated cells (Fig. 20a, lower 
panel). The treatment with HC had strikingly different effects on 
ErbB2/HER2 recycling, resulting in a strong stabilisation of ErbB2/HER2 at 
the cell surface and a high level of tyrosine phosphorylation (Fig. 20b and 
16a). For comparison, we treated the cells for equivalent time periods with 
the physiological ligand, HRG.  
 
 
 
Figure 20b: Effect of Herceptin® and HRG on the endocytosis of ErbB2/HER2. Serum 
starved MCF-7ADR cells were incubated at 4°C with 50 µg/ml HC or with 5 µg ml-1 α-
Heregulin (HRG) for 1 h, then washed two times with PBS and incubated at 37°C for the 
indicated timepoints. At the end of incubation, cells were biotinylated and lysed (see 
Method section). Cell lysates were subjected to immunoprecipitation (IP) using 
monoclonal anti-ErbB2/HER2 (α-ErbB2/HER2) antibodies (b, upper panel). Tyrosine 
phosphorylation level of whole cell lysates (WCL) was analyzed by western blotting (WB) 
with monoclonal anti-phosphotyrosine antibody (α-4G10) (b, lower panels). NS, 
unstimulated cells. 
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This also determined the downregulation of ErbB3/HER3 from the cell 
surface (although a relative increase in surface-ErbB3/HER3 was 
reproducibly observed after 2hs incubation, figure 20a lane 9), but the 
receptor, as expected, was still highly phosphorylated after two hours of 
incubation with the ligand. The effects of HRG pretreatment on 
ErbB2/HER2 downregulation were modest and a significant fraction of the 
receptor molecules were still on the cell surface after 3 hs of treatment 
(Fig. 20b, lanes 8-10). Mechanistically, we hypothesize that the strong 
general inhibitory effects of α-HER3ECD on HRG signalling could be due to 
increased ErbB3/HER3 endocytosis, which prevents the receptor from 
forming active signalling complexes with ErbB2/HER2 at the cell surface. 
The different effects of the two antibodies on the endocytosis rate of 
ErbB2/HER2 and ErbB3/HER3 could be due to their different epitope 
binding properties and effectiveness in inducing conformational changes in 
the receptor. 
 
5.12. The proliferative and migratory properties of 
breast cancer cell lines are inhibited by α-HER3ECD 
We then asked whether the ability of α-HER3ECD to attenuate HRG-
mediate activatory signals would also result in a functional output, i.e. the 
inhibition of growth and invasiveness of breast cancer cells. In order to 
assess the effect of α-HER3ECD on the migratory and proliferative 
properties of breast cancer cells, we performed BrdU-incorporation assays 
in the presence or absence of α-HER3ECD and stimulated with HRG. 
Pretreatment with α-HER3ECD decreased proliferation by 28.7% +/- 6.18% 
and 21.1% +/- 7.62% in MCF-7ADR and MDA-MB-468 respectively. HC, on 
the other hand, had no effect in these cell lines (data not shown) (Fig. 
21a). 
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Fig. 21a: α-HER3ECD inhibits the HRG-induced proliferation of breast cancer cell 
lines. MCF-7ADR and MDA-MB-468 were pretreated with α-HER3ECD for 1 hr and 
subsequently stimulated with HRG for 16 hr. BrdU incorporation was carried out as 
described in the Methods section. The results are the average of triplicate samples from 
at least four independent experiments. All data are expressed as means +/- standard 
deviation represented as error bars. Comparisons were made using Student’s t-test with 
P<0.05 being considered statistically significant. 
 
To investigate the effect of α-HER3ECD on the migratory properties of 
breast cancer cells, we conducted chemotaxis experiments with MCF-7ADR 
and MDA-MB-468 in the presence or absence of α-HER3ECD. We 
observed a strong decrease in migration of 59.1% (P=0.018) and 55.4% 
(P=0.00005) in MCF-7ADR and MDA-MB-468, respectively (Fig. 21b). Our 
data thus clearly show an inhibitory effect of α-HER3ECD on proliferation 
and migration in MCF-7ADR and MDA-MB-468. 
 
  
 
Results  74 
 
Fig. 21b: α-HER3ECD reduces the migratory response of breast cancer cell lines to 
chemoattractants. The cells were pretreated with α-HER3ECD for 1 hr, detached and 
transferred to the upper well of a Boyden Chamber. The assay was carried out in the 
presence of the chemoattractant for 16 hr as described in the Methods section. The 
migrating cells present on the lower side of the membrane were stained and counted. 
The results are the average of triplicate samples from two independent experiments. 
Statistical analysis was performed as described in figure 21a. 
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6. Discussion 
6.1. The role of ErbB3/HER3 in glioma invasion 
The cytoplasmic protein tyrosine kinase PYK2 lies at the convergence 
point of pathways that transmit signals from stimulated integrins, G 
protein-coupled receptors and RTKs to downstream effectors (Avraham et 
al., 2000; Dikic et al., 1996). An important stimulus that activates PYK2 is 
α-HRG (Zrihan-Licht et al., 2000). Both PYK2 and HRG are predominantly 
expressed in the central nervous system, and the genes encoding the two 
proteins are localised in close proximity to each other on chromosome 8 
(Inazawa et al., 1996). HRG is a promiscuous ligand for HER3 and 
ErbB4/HER4, members of the EGFR family of RTKs, which are among the 
most potent regulators of cell proliferation, differentiation and motility. In 
glioblastoma cell lines, which are devoid of ErbB4/HER4, binding of HRG 
leads to formation of ErbB2/HER2-ErbB3/HER3 heterodimers allowing 
transphosphorylation of ErbB3/HER3 by ErbB2/HER2 (Klapper et al., 
2000). The signalling molecules SHC and PI3-K are known to bind to the 
C-terminal region of HER3 and to promote cell growth (Klapper et al., 
2000; Wallasch et al., 1995; Yarden and Sliwkowski, 2001). These pieces 
of information, obtained in several model systems, prompted us to explore 
an HRG-stimulated signalling pathway involving ErbB2/HER2/HER3 and 
PYK2 in glioblastoma cell lines. Based on the data presented in this 
thesis, we propose a model in which PYK2 is phosphorylated by 
ErbB3/HER3 upon HRG stimulation, and induces cell motility and 
invasiveness through the MAPK pathway (Fig. 22). 
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6.1.1. PYK2 associates with ErbB3/HER3 
Immunoprecipitation assays indicate a constitutive association of PYK2 
with ErbB3/HER3, which is promoted by ErbB2/HER2 activity (Fig. 8b). 
This finding is supported by immunofluorescense studies, which confirmed 
a constitutive colocalization of these signalling molecules in a punctuated 
pattern throughout the cytoplasm independent of HRG stimulation (Fig 9). 
It is known that ErbB3/HER3 is internalised through the clathrin-mediated 
endocytotic pathway (Waterman and Yarden, 2001) and similar 
punctuated distributions have recently been shown for several proteins 
associated with this pathway, including mHip1r and EGFR (Engqvist-
Goldstein et al., 1999; Sorkina et al., 1999). Centripetal movement of the 
clathrin-coated vesicles towards the perinuclear region, which occurs on a 
time scale of several minutes, has been directly demonstrated by using a 
GFP-chlathrin fusion protein in Dictyostelium and COS-1 cells (Damer and 
O'Halloran, 2000; Gaidarov et al., 1999). A prolonged activation state of 
ErbB3/HER3/PYK2 complexes within endosomes during recycling would 
enable recurrent association of other signalling molecules and thus serve 
to amplify the initiating signal. This prolonged accessibility of 
ErbB3/HER3/PYK2 complexes and their transport towards the site of 
MAPK activity could explain the exceptionally strong mitogenic potential of 
ErbB2/HER2-ErbB3/HER3 heterodimers, compared to other members of 
the EGFR family (Klapper et al., 2000). Indeed, it has been shown that 
ErbB2/HER2-ErbB3/HER3 heterodimers are getting recycled, whereas 
EGFR-containing dimers are degraded via the ubiquitination pathway 
(Waterman and Yarden, 2001). 
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6.1.2. HRG stimulates PYK2 activation 
Although association of PYK2 with ErbB3/HER3 and its recycling appear 
to be HRG-independent, tyrosine phosphorylation of PYK2 is elevated by 
HRG stimulation. Our evaluation of the phosphorylation mechanism 
indicates that the kinase activity of ErbB3/HER3 is critical for this process 
(Fig. 10). Specifically, tyrosine residues Y1257, Y1270 and Y1288 in the 
C-terminal region of ErbB3/HER3 are important for PYK2 
transphosphorylation and its physical association with HER3. Furthermore, 
in vitro kinase assays substantiate the direct phosphorylation of GST-
PYK2-CT by endogenous ErbB3/HER3 and GST-HER3-KD (Fig. 10 and 
11). In selective inhibition experiments, we excluded ErbB2/HER2, src and 
PI3-K as proteins that directly phosphorylate PYK2. 
 
6.1.3. PYK2 is necessary for MAPK activation 
In addition, the dominant-negative PYK2-KM abrogates MAPK activation, 
suggesting that mitogenicity correlates with PYK2 activity (Fig. 13). It has 
been shown that cells overexpressing PYK2 exhibit elevated tyrosyl-
phosphorylated SHC and subsequent ERK-2 activity (Lev et al., 1995). We 
did not observe a direct interaction between PYK2 and SHC (data not 
shown), but it has been proposed recently that SHC associates with PYK2 
through GRB2 in platelets in dependence of αIIbβ3 integrin activation, thus 
linking extracellular signals to the Ras/Raf pathway (Ohmori et al., 2000). 
GRB2-binding to activated PYK2 could explain the subsequent tyrosine 
phosphorylation of SHC, which contributes to increased cellular 
downstream responses. Interestingly, PYK2-KM was also found to 
attenuate PI3-K activity (Fig. 14). ErbB3/HER3 harbours six potential 
docking sites for the SH2 domain of the PI3-K subunit p85, and one 
proline-rich sequence that forms a consensus binding site for the SH3 
domain of p85, all potentially contributing to a strong association of p85 
with ErbB3/HER3 (Hellyer et al., 1998). Furthermore, a constitutive 
association between PYK2 and p85 in platelets was reported, where a 
YXXM motif in PYK2 could serve for binding to the SH2 domain of p85 
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(Sayed et al., 2000). Indeed, immunoprecipitation of p85 from cell lysates 
revealed HRG-dependent association of tyrosyl-phosphorylated proteins 
of Mr= 113 kDa and 180 kDa, which were identified as PYK2 and 
ErbB3/HER3 (data not shown), suggesting that ErbB3/HER3, PYK2 and 
PI3-K are components of a multiprotein signalling-complex. 
 
6.1.4. ErbB3/HER3 is a kinase with narrow substrate specificity 
Previous studies analyzing ErbB3/HER3 have shown that its kinase 
activity is impaired due to the presence of non-consensus residues at 
positions 740 and 815 compared to all other tyrosine kinases, but made 
use of the artificial substrates poly(Glu80Tyr20) or Mn•TNP-ATP, which 
appear to be inadequate for ErbB3/HER3 (Guy et al., 1994; Sierke et al., 
1997). Additionally, ErbB3/HER3 kinase activity could not be detected in 
the myeloid cell line 32D, devoid of any ErbB proteins, which has been 
extensively used by many groups as a tool for investigating the 
ErbB2/HER2-ErbB3/HER3 signalling pathway (Yarden and Sliwkowski, 
2001). This result however could be explained by the fact, that 
ErbB3/HER3 is a kinase with narrow substrate specificity and that the 
substrate PYK2 is not expressed in 32D cells. On the other hand, 
structural and biochemical data are compatible with the ability of 
ErbB3/HER3 to phosphorylate PYK2, since ErbB3/HER3 can bind ATP 
and apparently possesses a functional kinase, although its activity is weak 
in comparison to the other EGFR family receptors (Guy et al., 1994; Sierke 
et al., 1997). In fact, a biochemical study clearly demonstrated that 
ErbB3/HER3 has an active kinase, which however is of two orders of 
magnitudes lower than the EGFR kinase activity (Guy et al., 1994). 
Furthermore, various groups have reported effects controlled by 
ErbB3/HER3 activation in the breast cancer cell lines BT483 and T47D, in 
the breast epithelial cell line MCF-10A and in the ovarian cancer cell line 
OVCAR-3, apparently independent of the contribution of other EGFR 
family members (Beerli et al., 1995; Rajkumar and Gullick, 1994). 
Although they hypothesised that ErbB3/HER3 could be the kinase 
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controlling the observed phosphorylation event, the authors favored the 
hypothesis that an as yet unidentified cytoplasmic kinase or another ErbB 
family member would be directly responsible for this effect (Beerli et al., 
1995). Clearly, the existence of additional EGFR family members that 
associate and cooperate with ErbB3/HER3 has not been revealed by 
sequence analysis of the human genome, which renders this possibility 
invalid. 
In a mechanistic model we propose that PYK2 is a key element in 
transmitting HRG-induced signals. Part of the signalling from PYK2 to 
ERK-2 is transmitted through PI3-K and SHC, but is also to some extent 
independent of ErbB2/HER2 (Fig. 13 and 14). These findings suggest that 
PYK2 is involved in the control of multiple downstream effectors, which 
modulate MAPK pathways (Fig. 22). 
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Figure 22: Role of PYK2 in ErbB2/HER2-ErbB3/HER3 signalling. The model indicates 
a novel signal transduction pathway, which leads from α-HRG stimulation to MAPK 
activation and induces tumour invasion. For details, see discussion. TM indicates the 
transmembrane domain, JM the juxtamembrane region. Arrows with an encircled B or P 
indicate binding and phosphorylation, respectively. 
 
6.1.5. Dominant-negative PYK2 suppresses tumourinvasion 
Finally, we show that the dominant-negative mutant PYK2-KM suppresses 
tumour invasiveness in three glioma cell lines (Fig. 15), which correlates 
with an inhibition of ERK-2 activity (Fig. 14). Interestingly, PYK2-KM 
abrogated invasiveness to the same extent as inhibition of MEK1 with 
PD98059, which strongly suggests that PYK2 via the MAPK pathway 
plays a key role in glioma invasion. It has been shown that ERK activity 
can regulate myosin phosphorylation, leading to actin-myosin association 
and cell contraction of the extracellular matrix, and that ERK can facilitate 
cell invasion and protect cells from apoptosis (Brunet et al., 1999; Nguyen 
et al., 1999). Concurrent with these findings, increased MAPK activity in 
our cell systems induced an increased invasive behaviour of glioma cells. 
Taken together, our data show that ErbB3/HER3 does not only cooperate 
with other EGFR family members by heterodimer formation, but that it also 
is an active kinase with an apparently very selective substrate specificity. 
In glioma cells, PYK2 is directly phosphorylated by ErbB3/HER3, which 
results in a potentiated PI3-K activity and enhanced signal through ERK-2, 
and a strongly invasive behaviour of the tumour cells. Our findings 
establish a new signalling pathway involving a functional connection 
between ErbB3/HER3 and PYK2 and provide a new basis for the 
development of therapies against invasive glioma. 
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6.2. ErbB3/HER3 as a target in breast cancer therapy 
ErbB2/HER2-ErbB3/HER3 heterodimers are fundamental regulators of 
breast cancer cell growth. Clinical studies have shown that the 
overexpression of ErbB2/HER2 and ErbB3/HER3 is associated with the 
lack of response to hormonal therapy, high malignancy and poor 
prognosis. The most highly metastatic breast cancer cell lines, on the 
other hand, lack the estrogen receptor and express endogenously HRG, 
which promotes their growth through an autocrine loop. Our results 
indicate that an antibody directed against the extracellular domain of 
ErbB3/HER3 efficiently decreases the tyrosine-phosphorylation of 
ErbB2/HER2 after HRG stimulation in the breast cancer cell lines MCF-
7ADR and MDA-MB-468; this inhibits the activation of downstream effectors 
and ultimately limits the proliferation and motility properties of the cells.  
 
6.2.1. α-HER3ECD promotes ErbB3/HER3 internalisation and inhibits 
tyrosine phosphorylation of ErbB2/HER2 
α-HER3ECD accelerates the endocytosis of ErbB3/HER3, thus resulting in 
the clearance of ErbB3/HER3 from the cell surface and potentially 
preventing HRG-mediated ErbB2/HER2-ErbB3/HER3 heterodimerisation. 
The inhibitory effects of α-HER3ECD are strikingly potent; this antibody 
counteracts the activity of the ErbB2/HER2-ErbB3/HER3 complex, the 
most active signal transducer among the EGFR family members, 
characterized by a slow endocytosis rate and by the ability of signalling 
throughout the internalization process. 
The action mechanism of the therapeutical anti-ErbB2/HER2 antibody 
Herceptin® in our cell system is substantially different, since Herceptin® 
induces hyperphosphorylation of ErbB2/HER2 and it does not abrogate 
the transphosphorylation activity of ErbB3/HER3 by ErbB2/HER2 after 
HRG stimulation. Herceptin® has been reported to sensitize breast cancer 
cells to TNF-alpha, Trance and various chemotherapeutics and to induce 
cell cycle arrest due to p27kip expression (Cuello et al., 2001; Lane et al., 
  
 
Discussion  82 
2001; Sliwkowski et al., 1999). Still, these effects are not sufficient to 
provide a tumour clearance in living organisms. A recent study by Clynes 
et al. has shown that the primary effect of Herceptin® is to stimulate the 
immune system by binding to the FcγR receptor (Clynes et al., 2000). 
They have elegantly demonstrated by gene targeting in mice that an 
antibody endowed with the ability to bind FcγR receptor, but not the 
FcγRIIB subtype, results in the complete tumour eradication from the 
organism. However, as extensively discussed by Clynes et al., the 
inhibition of the growth and invasion promoting signals within the tumour 
cell is predicted to increase the chances of the immune system to 
efficiently fight the malignancy (Clynes et al., 2000). Given that the 
inhibitory effects of α-HER3ECD on ErbB2/HER2-ErbB3/HER3 signalling 
are stronger than those of Herceptin®, the former antibody could be an 
even more effective chemotherapeutic agent, provided that it has an 
equivalent ability to activate the effector cells of the immune system.  
 
6.2.2. α-HER3ECD inhibits JNK signalling 
An important feature of α-HER3ECD is its ability to completely block JNK 
activity (Fig. 19). JNK is involved in the control of cell migration (Xia et al., 
2000) and several lines of evidence have also recently demonstrated the 
specific importance of JNK signalling in breast cancer cell motility and 
growth. Very invasive breast cancer cell lines were shown by microarray 
analysis to overexpress JNK (Zajchowski et al., 2001). Additionally, it has 
been shown that the prolylisomerase PIN1, overexpressed in breast 
cancer, cooperates with Ras in enhancing JNK activity; this, in turn, 
controls cyclin D1 promoter and increases the transcription of cyclin D1 
(Wulf et al., 2001). CyclinD1 is overexpressed in more than 50% of 
diagnosed breast carcinomas and has been shown to have a causative 
role in the pathogenesis of breast cancer induced by neu, the oncogenic 
variant of ErbB2/HER2 (Yu et al., 2001). α-HER3ECD abrogates JNK 
activity more efficiently than Herceptin® by interfering with SHC binding to 
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the C-terminal domain of ErbB3/HER3. Both α-HER3ECD and Herceptin®, 
on the other hand, efficiently inhibit PI3K activity, another important 
determinant of proliferation and invasiveness of breast cancer cells.  
Although the cell lines used in this study are characterized by a different 
ErbB2/HER2-ErbB3/HER3 ratio, namely 1:3 for MCF7-ADR and 3:1 for 
MDA-MB468. α-HER3ECD could effectively inhibit receptor tyrosine 
phosphorylation, proliferation and migration in both cases. This finding is 
of potential significance for the perspective therapeutical use of anti-
ErbB3/HER3 antibodies, because beneficial effects could be expected in a 
wide spectrum of clinical cases presenting different relative amounts of 
ErbB2/HER2 and ErbB3/HER3.  
Taken together, our data show that ErbB3/HER3, in association with 
ErbB2/HER2, plays a fundamental role in the control of breast cancer cell 
growth and invasiveness. Moreover, ErbB3/HER3 emerges for the first 
time as an important determinant of the breast cancer cell behavior as well 
as a target for drug design. Our findings provide a strong biological basis 
for the idea that counteracting aberrant ErbB3/HER3 signalling could be a 
primary objective in antibody-based breast cancer therapy.
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7. Abbreviations 
α anti- 
ADCC Antibody-dependent cellular cytotoxicity 
ATCC American type culture collection 
ATP Adenosintriphosphate 
BBS 2 x BES buffered Saline 
BES N-, N-Bis(Hydroxyethyl)-2-Aminoethane-Sulfoneacid 
bp Basepair 
CDC complement-dependent cytotoxicity 
cDNA complementary DNA 
Ci Curie 
DKFZ Deutsches Krebsforschungs-Zentrum 
DMSO Dimethylsulfoxid 
DNA Desoxyribonukleicacid 
DTT Dithiothreitol 
E.coli Escherichia coli 
EDTA Ethylendiaminetetraacetate 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
ER Estrogen receptor 
ERK-2 Extracellular-signal regulated kinase 2 
FCS Fetal Calfserum 
Fig. Figure 
g Gramm 
gp glycoprotein 
GST Glutathione-S-Transferase 
GRB 2 Growth factor bound 2 
h hour 
HC Herceptin® 
HEPES N-(2-Hydroxyethyl)-piperazine N’-2-ethanesulfoneacid 
HER2, 3, 4 human EGF-Receptor 2, 3, 4 
HRG Heregulin 
IP Immunoprecipitation 
kDa kiloDalton 
m meter 
M Molar 
mAB monoclonal antibody 
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MAPK Mitogen-activated protein kinase 
min minute 
ml Milliliter 
NDF Neu Differentiation  Factor 
NRG Neuregulin 
PAGE Polyacrylamide-Gelelectrophorese 
pAB polyclonal antibody 
PBS Phosphate-buffered Saline 
PCR Polymerase chain reaction  
PI3- Phosphatidyl-inositol-3-OH 
PMSF Phenyl-Methyl-Sulfonyl-Fluoride 
PY Phosphotyrosine 
PYK2 Proline-rich tyrosine kinase 2 
rpm Rounds per minute 
RT Roomtemperature 
RTK Receptortyrosinekinase 
s Second 
SDS Sodiumdodecylsulfate 
Tab. Table 
TGF Transforming growth factor 
Tris Tris(hydroxymethyl)aminomethane 
O/N over night 
UV Ultraviolet light 
V Volt 
VSV vesicular somatitis virus glycoprotein 
Vol. Volume 
WM Wortmannin 
WT wildtype 
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